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Abstract 
Cigarette smoking is a major public health issue in both developed and developing 
countries. There is estimated to be over a billion smokers in the world today, with 
almost one third of them living in China. In China, during the mid-1990s there were 
between 500,000 - 700,000 annual tobacco-related deaths. This predicted number of 
deaths could rise to nearly three million people a year by 2050. Many smokers in 
China want to quit, but Nicotine Replacement Therapy (NRT) is expensive in the East 
as the standard of living in China is a great deal lower than that in the West. The 
treatment costs more and the duration is about 4-6 weeks. Zhong Mai Yan Ke 
(Joymain Nicofree) - a Chinese herbal preparation for smoking cessation was 
produced in 1997 in China. It is claimed that Zhong Mai Yan Ke is effective but the 
claim has not been verified. In this study, the effectiveness of Zhong Mai Yan Ke was 
tested. 
Research Design 
Method: Open Randomised Controlled Trial (RCT). Sample: 64 volunteers were 
recruited based on a set of inclusion and exclusion criteria. 50 and 14 volunteers were 
allocated randomly to the treatment group and the control group. Intervention: 
Zhong Mai Yan Ke was given to the treatment group whereas the control group was 
given a placebo. Location: Dalian city in China. Results: 49 in the treatment group 
and 14 in the control group completed the study. The initial results at the end of the 9-
day treatment were 51.0% (n=25) managed to stop smoking; 34.7% (n=17) managed 
to reduce smoking consumption and 14.3% (n=7) failed to quit smoking. None 
(100%) in the control group managed to stop or reduce smoking consumption. Only 
few people in the treatment group suffered from side effects, such as nausea and 
dizziness. The follow-up results 3 months after the treatment were 43% (21 out of the 
25 quitters) managed to be ex-smokers; 38.8% (n=19) managed to reduce smoking 
consumption and 18.4% (n=9) failed to quit smoking. None (100%) in the control 
group managed to stop or reduce smoking consumption. No one suffered from any 
side effects 3 months after the trial. 
Conclusion 
Zhong Mai Yan Ke is an effective agent for smoking cessation. The findings of the 
present study suggest that Zhong Mai Yan Ke could be effective non-nicotine based 
herbal medicine for smoking cessation for worldwide use subject to further validation 
by other researchers. 
Table of Contents 
C H A P T E R 1: I N T R O D U C T I O N 1 
C H A P T E R 2: R E V I E W O F L I T E R A T U R E 11 
2.1 INTRODUCTION 11 
2.2 HAZARDS OF CIGARETTE SMOKING 12 
2.2.1 The effects of smoking 13 
2.2.2 The benefit of quitting smoking 14 
2.2.3 Problems of quitting 15 
2.3 E F F E C T I V E SMOKING CESSATION APPROACHES IN THE WORLD 17 
2.3.1 Social and health education 18 
2.3.2 Smoking cessation approaches mainly used in Western countries 20 
2.3.3 Traditional Chinese Medicine (TCM) in smoking cessation 28 
2.4 SUMMARY 33 
C H A P T E R 3: M E T H O D O L O G Y 35 
3.1 INTRODUCTION 35 
3.2 RESEARCH APPROACH: RANDOMISED CONTROLLED TRL^LLS 36 
3.3 OPEN RANDOMISED CONTROLLED T R L \ L 37 
3.4 STUDY DESIGN 40 
3.4.1 Background 40 
3.4.2 Recruitment 41 
3.4.3 Random allocation 42 
3.4.4 Intervention 42 
3.4.5 Data Collection 43 
3.4.6 Data Analysis 43 
3.4.7 Ethics 44 
3.5 LIMITATIONS 44 
3.6 SUMMARY 46 
C H A P T E R 4: C L I N I C A L T R I A L O F Z H O N G M A I Y A N K E 47 
4.1 INTRODUCTION 47 
4.2 FINDINGS 47 
4.2.1 Demographic Data and Baseline Characteristics 47 
4.2.2Effectiveness of Zhong Mai Yan Ke 52 
4:2.3 Side effects 64 
4.3 SUMMARY 66 
C H A P T E R 5: I N T E G R A T I N G A L L O P A T H I C M E D I C I N E A N D 
T R A D I T I O N A L C H I N E S E M E D I C I N E ( T C M ) 67 
5.1 T H E PRESENT SITUATION OF SMOKING AND SMOKING CESSATION IN THE 
WORLD 67 
5.2 SOME COMPARISIONS BETWEEN ALLOPATHIC INTERVENTIONS AND TRADITIONAL 
C H I N E S E M E D I C I N E ( T C M ) 69 
5.3 A CRITICAL ANALYSIS OF THE STUDY 71 
5.4 THE FUTURE RESEARCH DIRECTION 7 2 
5.5 SUMMARY 73 
B I B L I O G R A P H Y 74 
APPENDIX A : B O D Y ACUPOINT 82 
APPENDIX B i :POSTER 83 
APPENDIX B 2 : H E A L T H SCREENING QUESTIONNAIRE 84 
APPENDIX B3;SURVEY OF SMOKING STATUS AND CONSENT FOR THE TRIAL 86 
APPENDIX C : VOLUNTEER INTRODUCTION L E A F L E T 87 
APPENDK D : D A T E OF T H E TRIAL 88 
APPENDIX E : T H E L E T T E R FROM DALIAN UNIVERSITY IN CHINA 92 
Chapter 1 
Introduction 
Many of my friends are smokers. Although they are young people, it has been shovm 
that cigarette smoking is harmfiil to them, associated with cough, restlessness and 
insomnia. Their habits have affected other people too. For example, i f they smoke in 
public places such as the classroom or the dormitory the air is contaminated. Many of 
them wanted to quit but found it is too difficult to give up smoking. That is why I 
have carried out research related to smoking cessation. 
Epidemiologically, i f there is an effective way of helping smokers to quit, especially 
in developing countries such as China, wider benefit for these countries could be 
achieved. For example, it has been shown that in smokers, health can improve after 
giving up the habit. It is hoped, therefore, in the longer term the mortality rate will 
reduce and people wi l l live longer and healthier. As a result, poorer countries with 
large numbers of smokers wil l benefit economically from reduced health care costs 
and improvement in work productivity. 
Health consequences of smoking 
Gigarette smoking is a major public health issue in both developed and developing 
countries. Smoking causes more deaths than alcohol, microbial agents, toxic agents, 
firearms, high-risk sexual behaviour, and motor vehicle injuries combined (McGinnis 
& Foege, 1993). Smoking is a known detriment to health. The use of tobacco is 
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documented to increase the risk of heart disease, stroke, other vascular diseases, a 
variety of cancers and chronic obstructive pulmonary disease (USDHHS, 1990). 
Smoking during pregnancy substantially increases the risk of spontaneous abortion, 
prematurity, low birth weight, and perinatal mortality (Benowitz, 1991). 
Tobacco is the single most important avoidable cause of chronic il l health and 
premature death in developed countries, where it now causes a quarter of all the 
deaths in middle age with maximum mortality among males and rising mortality 
among females. In developing countries many men now smoke, and mortality from 
tobacco is increasing. Worldwide, i f current smoking patterns persist, it has been 
predicted that smoking related deaths wil l increase from three million in the early 
1990s (which is 10% of all adult deaths) to ten million by the late 2020s (World 
Health Organization, 1996). 
In China, lung cancer and other smoking related diseases are the most common causes 
of death. There were between 500,000 - 700,000 annual tobacco-related deaths during 
the mid-1990s (http://www.cdc.gov/tobacco/who/china.htm) which is equivalent to 
10,000 people dying every week (http://www.hhs.se/eijs/anomaly/CSsmoking.htm). 
The mortality among males is higher than that in females in China. Dr. Yang of 
Chinese Academy of Preventive Medicine 
(http://www.ctsu.ox.ac.uk/tobacco/chmed.htm) said: "Men in China smoke far more 
cigarettes than they used to, but, surprisingly, women in the cities of China show the 
opposite pattern from men. Before 1950, 10% of young women became smokers, but 
for unknown reasons this plummeted: now only 1% do. However, there is still a 
danger of a large increase." In 1998, 12% of all adult male and 3% of all adult female 
deaths were caused by smoking. In the West, smoking causes a high number of heart-
related deaths, but in China, the majority of deaths are due to respiratory diseases 
(http://news.bbc.co.Uk/l/hi/health/216998.stm). Professor Liu from Chinese Academy 
of Medical Sciences (http://www.ctsu.ox.ac.uk/tobacco/chmed.htm) said: "about 45% 
of China's smoking deaths are from chronic lung disease, 15% from lung cancer and 
5-8% from rcombination of oesophagus cancer; stomach cancer, liver cancer, stroke, 
heart disease and surprisingly, tuberculosis." Although smoking causes more deaths 
from chronic lung diseases than from lung cancer, the reverse of what happens in the 
West, the death from lung cancer caused by smoking is still showing a rising trend. 
For example, the rates of adult deaths per 100,000 from lung cancer were reported as 
56.8 for males and 23.5 for females in 1995 compared to 49.3 and 20.6 in 1985-89 in 
China (http://www.cdc.gov/tobacco/who/china.htm). The contributory factor to the 
rising number of tobacco related deaths is thought to be caused by smokers not being 
convinced of the health risks associated with cigarette smoking. Surveys showed two-
thirds of people in China think smoking does little or no harm, 60 % think it does not 
cause lung cancer and 96% do not know that it causes heart disease 
(http://news.bbc.co.Uk/l/hi/health/216998.stm). I f current smoking patterns persist, it 
is predicted there will be two million tobacco-related deaths by 2025 
(http://www.cdc.gov/tobacco/who/china.htm). By 2050, researchers expect this 
number could rise to 8000 a day which is equivalent to some three million people a 
year (http://news.bbc.co.uk/1 /hi/health/216998.stm). 
Internationally, the increasing prevalence of smoking in third world countries and in 
Eastern Europe is expected to give rise to increasing numbers of deaths worldwide in 
the early decades of this century. It is difficuh to give precise figures but, i f current 
smoking patterns persist, the current estimate of three million deaths annually in the 
world as a whole is likely to rise to 10 million a year in about 30 years' time (Peto et 
al, 1994). 
Smoking is the leading preventable cause of death in the United States (USDHHS, 
1990). Nearly half a million Americans die annually as a result of smoking: 400,000 
from the direct effects of smoking (Centres for Disease Control and Prevention, 1993) 
and 50,000 from second hand smoke (Houston et al, 1994). Smoking-related illnesses 
account for about 20% of all deaths in the United States. It has been estimated that on 
average, of one thousand 20 year olds in the United States who smoke cigarettes 
regularly, about six will die from homicide, about 12 from motor vehicle accidents, 
about 250 will be killed by smoking in middle age and another 250 in old age (Peto et 
al, 1994). 
Smoking is the single greatest cause of preventable illness and premature death in the 
UK. Smoking kills over 120,000 people in the UK a year - more than 13 people an 
hour. Smoking causes 46,500 deaths from cancer a year in the UK - three out of ten 
cancer deaths. Smoking causes 84% of deaths from lung cancer, and 83% of deaths 
from chronic obstructive lung disease, including bronchitis. Smoking causes one out 
of every seven deaths from heart disease - 40,300 deaths a year in the UK from all 
circulatory diseases (Callum, 1998). Cigarettes were responsible for about 1.2 million 
deaths in the European Region of the World Health Organisation in 1995, almost 
three quarters of a million of which occurred in middle age i.e. 35-69 years (Peto et al, 
1994). 
Passive smoking, or second-hand smoking, which can be defined as non-smokers 
breathing in other people's tobacco smoke, also kills. Exposure to environmental 
tobacco smoke is a cause of lung cancer. For example, several hundred people a year 
in the UK are estimated to die from lung cancer brought about by passive smoking 
(Hackshaw et al, 1997). It has been suggested that passive smoking almost certainly 
contributes to deaths from heart disease - an even bigger killer than lung cancer (Law 
et al, 1997). In the USA, about 50,000 die from second hand smoke annually 
(Houston et al, 1994). In China, there are now about 450 million passive smokers 
(http://www.usembassy-china.org.cn/english/sandt/smoking.htm). 
In addition, smoking in the presence of infants and children is a cause of serious 
respiratory illness and asthmatic attacks. Sudden infant death syndrome, the main 
cause of post-neonatal death in the first year of life, has been claimed to be associated 
with exposure to environmental tobacco smoke. The association is judged to be one of 
cause and effect (The Stationary Office, 1998). 
The problems of smoking worldwide 
1. The prevalence of smoking in China 
There is estimated to be over a billion smokers in the world today. There are 
1,270,000,000 people in China in 2000 representing 20 % of the world's population 
and they consume 30% of the world's cigarettes 
ihttp_.:.//www.hcc.hawaii.edu/~pine/phil 110/chinasmoking,htm). J n J 995, 61% of men 
^but.only,7% of ^pmen sm ^ 
(http://www.usembassy-china.org.cn/english/sandt/smoking.htm). In the year 2000 
there were 350,000,000 smokers in China which constitutes about 1/3 of the total 
Chinese population, accounting for about 1/4 of the total smoking population in the 
world (http://www.chinatoday.eom/data/data.htm#Hel). 
The incidence of smoking is on the increase as is the consumption of cigarettes. For 
example, the number of cigarettes consumed per adult each year in China rose from 
700 in 1970 to 2000 in 1990/1992 (almost all of which are smoked by men) ( Doll, 
1996). Tobacco is increasingly consumed in the form of manufactured cigarettes 
(http://www.cdc.gov/tobacco/who/china.htm). This is shown in Figure 1.1. 
Figure 1.1 Consumption of Manufactured Cigarettes in China 
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It was reported in 1984 that smokers in China smoke on average 16 cigarettes per day 
and that the average age of first smoking in China is 25 years old. A more recent 
report indicates that people start smoking three years younger than previously 
reported (http://www.chinatoday.eom/data/data.htm#Hel). 
2. The prevalence of smoking in other countries 
Intemationally,-there"are around T3 million adult smokers in the UK (The Stationary 
Office, 1998). Smoking peaked in the 1950s and 1960s, and fell steadily in the 1970s 
and 1980s (Wald et al, 1988). But the long downward trend in smoking may be 
levelling out. Adult smoking rates rose in 1996, the last full year for which figures are 
available, for the first time since 1972. We may be seeing the beginning of a new 
upward trend in smoking. Among people aged 16 and over, the smoking rate of 28% 
in England was the same as in 1992 and was up on the 1994 rate of 26% (Thomas et 
al, 1998). The adult smoking rate is particularly high in Scotland and Wales at 32% 
(Thomas et al, 1998; Health in Wales Survey, 1996). In Northern Ireland it is 29% 
(Northern Ireland Statistics and Research Agency, 1997). 
Smoking in third world countries is increasing. For example, the US Centres for 
Disease Control and Prevention show smoking has risen in sub-Saharan Africa where 
cheap brands are available and tobacco companies are using intensive advertising and 
marketing campaigns, sponsorship of events and cigarette price wars (The Stationary 
Office, 1998). 
The picture for teenagers smoking is much worse. For example, in the UK, the 
percentage of regular smokers aged 11-15 was reported to be 13% in 1984. Between 
1984 and 1994, the percentage reported dropped as low as 8%, but rose again in 1994 
to 12% (HMSO, 1997; HMSO, 1992; HMSO, 1995; Health Education Board for 
Scotland, 1994). It was reported in 1996 that the prevalence of young people smoking 
had risen again to 13% (Jarvis, 1997; Barton & Jarvis, 1997). Recent records also 
show that 17,000,000 cigarettes are smoked every week in the UK by children of 11-
15 years of age (Cheung & Woof, 2001). In the USA, there are 3,000 new smokers 
every day so the quantity of smokers increases by 1,000,000 every year. In France, the 
rate of smoking has reduced since 1977, but young people aged from 12 to 18 who 
smoke is still 35%. Although the rate of young people smoking remains 18%-19% in 
Australia and Canada, it has increased to 50% in some cities (Specialized Information, 
1997). In China, in the year 2000, about 50 million smokers were teenagers 
(http://www.chinatoday.eom/data/data.htm#Hel). 
Economic costs of smoking 
The cost'of smoking is high in terms of people's health. But the cost of smoking is 
high in other ways too. The health consequences of cigarette smoking carry an 
enormous economic burden. 
In China, a pack of 20 local cigarettes costs between US $0.20 to US $4.20, although 
most are cheaper than the imported cigarettes which cost about US$ 2.00 in 1990. It 
was estimated that 20 cigarettes cost 25% of average daily income, up from 10-14% 
in 1987 (http://www.cdc.gov/tobacco/who/china.htm). 
In the UK, treating illness and disease caused by smoking is estimated to cost the 
NHS up to £1.7 billion every year (Buck et al, 1997). It costs families, especially the 
poorest, a great deal too. It is estimated that, in 1996, there were approximately one 
million lone parents on Income Support, of whom 55% smoked an average of five 
packs of cigarettes a week at a cost of £2.50 per pack (Dorset & Marsh, 1998). That 
means lone parent families spent £375 million on cigarettes during that year (The 
Stationary Office, 1998) 
In the USA, a conservative analysis estimated that the direct medical care costs 
attributable to smoking in 1993 reached nearly $50 billion (Centre for Disease Control 
and Prevenfion, 1994b). These estimates do not include other direct medical costs, 
such as treatment for burns resulting from smoking-related fires, perinatal care for 
low-birth weight infants of mothers who smoke, and costs associated with diseases 
caused by exposure to environmental tobacco smoke. In addition to the direct medical 
costs, there are indirect non-medical costs resulting from smoking-related morbidity 
and premature mortality, such as lost productivity, missed work, and higher healthcare 
coverage costs for businesses (Lesmes, 1992). In 1990, the value of lost productivity 
resulting from premature deaths of smokers and former smokers was estimated to be 
$40.3 billion. The indirect cost of morbidity (resulfing from work loss and bed-
disability days, for example) was estimated to be $6.9 billion (Centre for Disease 
Control and Prevention, 1994b). Combined, the direct medical and indirect non-
medical costs associated with smoking-related morbidity and mortality approach $ 100 
billion annually. 
Evidence supports the assertion that cigarette smoking is a global public health 
problem. It affects both active and passive smokers. In spite of the increased attention 
given to health education warning people about the risks associated with cigarette 
smoking, the warnings are unheeded by smokers and intending smokers, particularly 
young people. 
One of the problems of cigarette smoking is the effect on productivity in the 
developed countries and in the developing world. Cigarette smokers are absent from 
work about 6.5 days more per year than non-smokers. They average six more visits to 
healthcare facilities each year than non-smokers, and their dependents make about 
four more visits per year than non-smokers. Furthermore, smokers may be less 
productive on the job. In workplaces where people leave their stations to go to 
designated areas in order to smoke, smokers spend 8% or more of their time involved 
in smoking-related activities (Lesmes, 1992). Particularly, cigarette smoking will 
impact on the economic development of developing countries where many working 
adults who are smokers will die earlier than expected. It can be deduced 
demographically that countries where the population is denser wil l be more affected. 
China is the biggest developing country and the number of deaths caused by smoking 
will be greater than that in the UK, America and in other developed countries. 
The other problem is that smokers find it difficult to give up the habit once the 
addiction has been established. Approximately 70% of cigarette smokers' report that 
they want to quit (Centre for Disease Control and Prevention, 1994a) and every year 
more than one third of smokers make at least one attempt to quit (Hatziandreu et al, 
1990). Less than 10% of smokers who attempt to quit are successfial each year (Centre 
for Disease Control and Prevention, 1994c). Although about half of all people who 
have ever smoked cigarettes have now stopped, (Centre for Disease Control and 
Prevention, 1994a), most attempted to quit several times before succeeding (Amsten, 
1996). 
Currently, many approaches have been developed to help people stop smoking. 
Routine advice by family doctors, encouragement, and psychological approaches have 
been tried in developed countries. Nicotine replacement therapy, NRT products, 
combined pharmacological and psychological treatment has been introduced too. 
However, methods available to help smokers to quit are not completely effective. For 
example, nicotine replacement products are said to be effective but these products 
have shown to produce side effects and some side effects are serious. For example, 57 
deaths are claimed in relation to Zyban, a centrally acting anti-smoking medication. 
(http://uk.news.yahoo.com/020117/80/cpnrf html). New research should be 
encouraged in smoking cessation using different approaches and other products which 
are not previously known through research and publications. 
Traditional Chinese Medicine (TCM), including acupuncture and Chinese herbal 
preparations, have been used in the Far East and are claimed to have been successful 
in helping smokers to quit. Herbal preparations have been used in China for thousands 
of years. Recently, a Chinese herbal patch "Zhong Mai Yan Ke" based on the theories 
of herbs and meridians and collaterals was introduced for smoking cessation. The 
product has been readily commercially available in herbal shops in China and is 
commonly used. It has been judged safe for public use. It has been claimed that it has 
helped one million smokers to give up the habit after one (9 days) or two (18 days) 
courses of treatment. However, such claims cannot be substantiated as there has been 
no systematic investigation. 
The purpose of this open label therapeutic trial is to establish the extent of the effect 
of Zhong Mai Yan Ke as an effective smoking cessation agent and to ascertain any 
side effects from the product. In addition, this study is to confirm the acceptability of 
the use of placebo in a commercial and specific culture setting in China. The 
following hypotheses wil l be tested: 
(1) Zhong Mai Yan Ke is an effective agent achieving a 30% quitting rate at the 
end of a 9-day treatment 
(2) Zhong Mai Yan Ke is effective in the long term achieving a 20% quitting rate 
three months after the trial 
(3) There are no serious side effects associated with the use of Zhong Mai Yan Ke 
(4) It is feasible to organise an open label randomised controlled trial in a 
commercial, and specific cultural setting in China. 
This thesis is organised into five chapters. Chapter two is the literature review. It 
presents the main reasons for difficulty in quitting smoking - nicotine addiction. It 
also evaluates the effectiveness of smoking cessation approaches; especially Nicotine 
Replacement Treatment (NRT) products. The role of Traditional Chinese Medicine 
(TCM) including acupuncture and an approved herbal preparation Zhong Mai Yan Ke 
in particular is introduced. 
Chapter three provides a background description of the area in which the trial took 
place and presents the aims pursued and the methodology used in this project. The 
reasons why the method was selected and explanation of the advantages and 
disadvantages are given. 
Chapter four presents the findings of the trial. 
Chapter five discusses the possibility of integrating allopathic medicine with 
Traditional Chinese Medicine (TCM) for smoking cessation and presents a critical 
analysis of the methodology, a summary of the results and their interpretation and 
suggestions for further research in this field. 
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Chapter 2 
A Review of the Literature 
2.1. Introduction 
Many smokers want to kick the habit but it is very difficult for them to give up 
unaided because of the pharmacological effects of the nicotine. One of the problems 
often experienced by smokers while trying to give up cigarettes is the desire to smoke 
on a regular basis caused by fluctuating plasma nicotine level and the associated 
symptoms of craving (Cheung & Childs, 1996). Ex-smokers have found that craving 
can be overcome by various distractions or goals, direct activities such as exercise and 
hobbies (CHS, 1996). Self determination or will power is considered more important 
than anything else. 
Other researchers recognised that giving up smoking is a process and not a simple 
decision to give up suddenly. There are various stages of behaviour change associated 
with smoking cessation (Prochaska & Di Clement, 1992). Prochaska's theory 
postulates that smokers go through various stages of behaviour change, i.e. from pre-
contemplation to contemplation, preparation, action and maintenance. Researchers in 
this field of work appear to apply Prochaska's theory in their work, but, the theory 
appears to contradict practical experience of many ex-smokers (CHS, 1996) 
This thesis focuses on active interventions which are claimed to have helped smokers 
to successfully relinquish their habit. This chapter will begin with a brief review of 
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the hazards associated with cigarette smoking, and then proceed to review the 
following topics: 
• The methods used in countries where smoking cessation has been integrated in 
primary health care, in particular, where pharmaceutical products have been 
prescribed for smokers. 
• Other non-nicotine based products 
• The methods used by Traditional Chinese Medicine practitioners 
2.2. Hazards of cigarette smoking 
Cigarette smoke contains in excess of 4000 substances. The components most often 
linked to adverse effects are nicotine, tar and carbon monoxide (Table 2.1) (Quit, 
1994). 
Table 2.1 The contents of tobacco smoke 
Tar 
A mixture of over 1,000 chemicals, including a variety of irritants and at 
least 60 known carcinogens 
Nicotine 
It is an addictive element. It is absorbed very rapidly from the lungs into the 
bloodstream, and reaches the brain after about seven seconds. Through its 
actions on the autonomic nerves, nicotine raises heart rate and blood 
pressure. 
Carbon monoxide 
Also found in car exhaust fumes, it displaces oxygen from haemoglobin, 
causing a reduction in the oxygen carrying capacity of the blood. This is 
particularly important in pregnant women and those with vascular disease. 
Other chemicals 
Hydrogen cyanide, benzene, ammonia and formaldehyde are all present in 
small quantities. 
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2.2.1 The effects of smoking 
The use of tobacco is documented to increase the risk of heart disease, stroke, other 
vascular diseases, a variety of cancers, and chronic obstructive pulmonary disease 
(USDHHS, 1990). According to the US Surgeon General, the younger children start 
smoking, the younger they are likely to die from cancer (USDHHS, 1982). 
Smoking in pregnancy causes adverse outcomes, notably miscarriage, reduced birth 
weight for gestation and perinatal death. Where parents continue to smoke after 
pregnancy there is an increased rate of sudden infant death syndrome (The Stationary 
Office, 1998). Of particular concern is the effect on children of smokers, either 
smoking mothers or non-smoking mothers with smoking partners. Smoking can cause 
problems, such as increased foetal and neonatal mortality, low birth weight, delayed 
physical and mental development of children and respiratory illness in infants and 
young children (Taylor, 1992). 
Smoking in the presence of infants and children is a cause of serious respiratory 
illness and asthmatic attacks. Sudden infant death syndrome, the main cause of post-
neonatal death in the first year of life, is associated with exposure to environmental 
tobacco smoke. The association is judged to be one of cause and effect (Quit, 1994). 
Particularly, studies of teenagers have shown that pharmacological factors become 
important very early in the smoking career. By the time daily smoking is established, 
within only a few months of starting, children take in as much nicotine per cigarette as 
do dependent adult smokers (McNeil & Jarvis, 1989). Children as young as 14-15 
years report experiencing nicotine withdrawal effects, and perceive that stopping 
smoking will be hard to achieve successftiUy (McNeil, 1991). These observations 
confirm the US Food and Drug Administration's view of cigarette smoking as a 
"paediatric disease" (Kersler et al, 1997). 
Non-smokers can be harmed by smoking as well. Non-smokers involiiritary inhale 
tobacco smoke when in the presence of people who are smoking. The smoke breathed 
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in by non-smokers is 85% side stream and 15% exhaled mainstream smoke. This 
smoke contains more than 4000 chemicals and at least 40 known carcinogens as well 
as nicotine. Many toxic constituents are found in higher concentrations in side stream 
than in mainstream smoke. Non-smokers continue to inhale smoke even when the 
cigarette is extinguished because smoke can persist in internal environments for many 
hours, depending on ventilation and mixing of room air with uncontaminated air. 
Smoking affects the smoker's family, friends and work colleagues, plus people 
encountered in public places. These people are at risk of the same diseases as the 
smoker. For example, risk of death from heart disease is about 30% higher amongst 
non-smokers exposed to smoke in the home. This figure is probably higher for people 
exposed in the workplace (Taylor, 1992). 
2.2.2 The benefit of quitting smoking 
The main benefit of quitting smoking is improved smokers' health. Quitting smoking 
can reduce or even put an end to long-time diseases, such as heart disease, stroke and 
lung cancer (Specialized Information, 1997). 
Short and long term effects of ceasing to smoke: 
• 20 minutes: Blood pressure and pulse rate return to normal. Circulation improves 
in hands and feet, making them warm. 
• 8 hours: Oxygen level in the blood returns to normal. Chances of a heart attack 
start to fall 
• 24 hours: Carbon monoxide is eliminated from the body. The lungs start to clear 
out mucous and other debris. 
• 48 hours: Nicotine is no longer detectable in the body. The ability to taste and 
smell is improved. 
• 72 hours: Breathing becomes easier as the bronchial tubes relax. Energy levels 
increase. 
• 2-12 weeks: Circulation improves throughout the body, making walking easier. 
• 3-9 months: Breathing problems such as cough, shortness of breath, and wheezing 
imprpxe. OyeraU 
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• 5 years: Risk of a heart attack falls to about half that of a smoker. 
• 10 years: Risk of lung cancer falls to about half of that found in a smoker. Risk of 
a heart attack falls to about the same as someone who has never smoked. 
2.2.3 Problems of quitting 
Although approximately 70% of cigarette smokers report that they want to quit 
(Centre for Disease Control and Prevention, 1994a), it is very difficult to give up the 
habit due to the pharmacological effects of nicotine on the central nervous system. 
1. Long-term side effects 
Although the long-term side effects have been confirmed, it is difficult for smokers to 
appreciate that they are in danger of the possibility of chronic diseases which have not 
yet appeared. When a person is smoking, some physiological changes occur, such as 
increasing heart rate, rising blood pressure and other problems such as oral ulcers, 
cough in the morning, increase in the reflux of gastric acid, periodontal disease, 
increasing levels of nervous mood or worry, impotence and sterility, aggravation of 
asthma and skin conditions (Zhang, 2000). However these changes happen gradually 
so that smokers do not pay attention to them and cannot make a decision to quit at 
once. 
2. Addiction to nicotine - the main reason of quitting unsuccessfully 
The Surgeon General of the Department of Health and Human Sciences of the US 
Government claim that the central element amongst all forms of drug addiction is that 
the user's behaviour is largely controlled by a substance that produces transient mood 
changes where the brain acts as the mediator. Secondly, the drug is sufficiently 
rewarding to warrant repeated administration; for example, smokers recognise the 
relief from stress that can be gained from continuing smoking. Thirdly, once the 
toleraiice to the drug is established, a given dose of drug produces less effect, so that 
increased doses or increased frequency of usage are required to maintain the intensity 
of effect. Finally, there is impulsive use: those smokers feel the urge to smoke, despite 
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the potential risk of damage to themselves or society (USDHHS, 1988). 
Nicotine is the drug in tobacco that causes addiction, and the pharmacological and 
behavioural processes that determine tobacco addiction are similar to those that 
determine addiction to heroin and other addictive drugs. For example, once the 
smoking habit is established, the need to smoke to maintain a required level of 
physical and mental alertness is controlled by the half-life (the speed at which a 
chemical becomes disintegrated) of nicotine. Nicotine has a half-life between two and 
four hours, depending on the metabolic rates of individuals. The need to smoke is 
completely dependent on the level of plasma nicotine present in the circulation. This 
dependency can be explained by the effects of the nicotine regulatory model (Knapp 
et al, 1963; Lucchesi et al, 1967). Initially, nicotine produces the desired 
pharmacological effects such as alertness, muscular relaxation, and so forth, which are 
effectively termed the initial affective reaction. At the same time, these "positive" 
effects bring about the "slave-type" negative effects, the hedonic effects, in the sense 
that the body needs the cigarette to produce the positive effects. Both the positive and 
negative effects are constantly reinforcing each other. As the smoking experience 
continues, the negative effects take on a more dominant role, in that the habit of 
smoking is driven by internal and external cues such as fluctuating plasma nicotine 
levels and hostile environments, for example environments or tasks that smokers see 
as being burdensome or unpleasant, which ftirther reinforce the negative effects. 
Consequently, there is an urge to smoke regularly (Cheung & Woof, 2001). 
Further research conducted during the past decade shows that the mesolimbic 
dopamine system, which is involved though the neurobiology of nicotine addiction is 
not completely understood (Nisell et al, 1995). Dopamine appears to play an 
important role in the physiologic mechanism for the experience of "pleasure". This 
system is commonly described as the "reward pathway." Al l known drugs of abuse, 
including nicotine, stimulate increases in dopamine along this pathway (Leshner, 
1996)^ 
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The withdrawal pathway is believed to arise from the locus ceruleus and to involve 
norepinephrine (Leshner, 1996). This pathway presumably mediates pathophysiologic 
symptoms such as the cravings, irritability, and difficulty concentrating that 
characterizes withdrawal from an addictive substance. 
Normally, dopamine-containing vesicles release dopamine into the synapses. 
Dopamine then is either quickly absorbed or broken down by the enzyme monoamine 
oxidase B (MAO-B). Nicotine increases the amount of dopamine within the synapses 
by stimulating the release of dopamine, while another substance in cigarette smoke 
(which remains to be identified) blocks the action of MAO-B (Leshner, 1996). 
According to the latest research in the biology of addiction, the drug-addicted brain is 
qualitafively different from the non-addicted brain. First, the long-term effects of 
nicotine and other addictive drugs on the brain include a persistent decrease in 
glucose metabolism and intraneuronal changes in gene expression. There also appear 
to be persistent alterations in the brain's responsiveness to envirormiental cues, which 
can induce drug craving and drug-seeking behaviour (Leshner, 1996). 
Even though nicotine alters the brain's systems, it is important to keep in mind that 
nicotine addiction is more than just a neurological disease. Addiction occurs in a 
particular set of environmental, historical, and physiologic contexts that affect the 
way drug use interacts with the brain (Leshner, 1997). Therefore, effective treatment 
of nicotine addiction requires simultaneous targeting of biological and behavioural 
aspects of the disorder (Leshner, 1996; Leshner, 1997). 
2.3 Effective smoking cessation approaches in the world 
Although most smokers want to quit, they experience well-recognised barriers and 
withdrawal symptoms during their attempts to quit, and they are largely unsuccessfial 
in quitting. Social movement and all kinds of medicine or therapies for quitting 
smoking, i.e. Nicotine Replacement Therapy (NRT), non-nicotine drugs, acupuncture 
and herbal medicine, were tried to help smokers to quit in Western and Eastern 
countries. 
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2.3.1 Social and health education 
There have been anti-tobacco laws in the majority of Western countries for at least 20 
years. These laws have been introduced gradually and include restrictions on direct 
advertising, minimum age requirements for purchase, and explicit warning labelling 
requirements. It is generally believed that these laws are responsible for the decline in 
smoking in the West (http://www.hhs.se/eijs/anomaly/CSmoking.htm). 
In the United Kingdom, smoking cessation has tended to focus on brief interventions 
which can be delivered by mass media or by non-specialists to a large number of 
smokers, e.g. National No Smoking Day, quit lines, nicotine replacement products 
available from pharmacists and brief advice from health professionals. Though these 
may encourage large numbers to quit, most smokers (97%) do not succeed in quitting 
long-term after an unaided quit attempt. The relapse rate is very high (Foulds & 
Ghodse, 1995). 
Norway, Finland and Iceland all introduced advertising bans back in the 1970s which 
were followed by large reductions in smoking rates or tobacco consumption (Joosens, 
1997). The Canadian government handed out manuals between 1992 and 1995 to help 
adolescents quit smoking (Zhang & Ma, 1999). 
Cambodia produced 10,000 anti-tobacco stickers and broadcast anti-tobacco messages 
on television On World No-Tobacco Day in 1993. The Minister and Vice-Minister of 
Health made personal commitments to the Tobacco or Health message. During the 
celebration of World No-Tobacco Day 1994, amidst extensive media coverage, the 
Minister of Health requested the Council of Ministers to ban tobacco advertising in 
public places (http://www.cdc.gov/tobacco/who/china.htm). 
China introduced its first anti-tobacco law at the beginning of 1992. The law contains 
four health clauses which include: reduction of tar and printing of tar levels and a 
health warning on cigarette packs; bans/control of smoking on public transport and in 
^public places; bans on smoking by elementary-and^high school students;^bans on 
tobacco advertising on TV, radio, and in newspapers and magazines. Increased health 
education on the dangers of smoking is also required by law. Subsequently, China has 
banned advertising in other media, such as billboards, television 'infomercials', and 
sponsorship of sports, arts, and music. In 1995, a national Advertisement Law 
extended the advertising ban to waiting rooms, cinemas and theatres, meeting rooms, 
sports stadium, etc. (http://www.cdc.gov/tobacco/who/china.htm). Even more 
recently, in 1996, further regulations were introduced banning smoking in hospitals, 
schools, museums, shops, and other public places. It can be seen that China is 
approximately 15-20 years behind the West in regards to widespread awareness and 
official smoking regulations (http://www.hhs.se/eijs/anomaly/CSmoking.htm). 
The Chinese government strengthened the protection for non-smokers. Smoking was 
banned in many public places, and in some workplaces (usually because of fire 
hazard). Since 1949, the government has carried out a policy that smoking was asked 
being harmed on public transport vehicles in all big cities from the start of the 
communist regime. Anyone who smokes on public transport vehicles would be fined. 
Smoking was asked being harmed on subways, and in 1986, no-smoking sections 
were introduced on trains. Al l domestic flights have been totally smoke-free since 
1983 and since 1995, all flights became smoke-free. Smoking is banned in Ministry of 
Public Health premises, and is partially banned in hospitals and health facilities 
(http://www.cdc.gov/tobacco/who/china.htm). 
Health education is improved constantly. The first recommendation by doctors for 
action against tobacco was in 1979, and health information campaigns commenced in 
the 1980s. The first "No-smoking Day" was held in 1987, and since 1988 WHO's 
World No-Tobacco Day has been celebrated nationally every year; it is reported that 
cigarettes are not sold throughout China on that day. The Rural Farmers Quitting 
Project organized by the National Health Education Institute, is a smoking cessation 
program targeting illiterate, rural farmers 
(http://www.cdc.gov/tobacco/who/china.htm). Other developments indicating a move 
away from cigarette acceptance include Chinese participation in international 'Quit 
and Win' contests - In 1996 China had the largest number of contestants in this contest 
(15,000 out of 66,00^) (http://www.hhs.se/eijs/anomaly/CSmoking.htm). 
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2.3.2 Advantages and disadvantages of smoking cessation approaches used in 
Western countries 
1. Advice and encouragement 
The resuhs of the review (Law & Tang, 1995) show that simple, brief, unsolicited 
advice from a general practitioner (GP) is effective in increasing rates of smoking 
cessation. An estimated 2% of smokers, given advice by their GPs, stopped smoking 
and did not relapse up to one year as a direct consequence of such advice. The 
Cochran Collaboration review confirmed the effectiveness of GP smoking cessation 
advice (Silagy et al, 1997). This form of intervention is extremely cost effective. 
Additional interventions, supplementary to simple advice, such as follow up letters 
and visits, show mixed results. 
Advice and encouragement to stop smoking are known to be more effective in some 
groups, particularly high risk groups such as pregnant women and patients who have 
ischaemic heart disease or who have recently had a heart attack. There is no available 
evidence on interventions in sufferers from asthma or in others at times of stress, such 
as prospective fathers or people awaiting elective surgery under general anaesthesia 
(The Stationary Office, 1998). 
2. Nicotine Replacement Therapy (NRT) 
It is claimed that Nicotine Replacement Therapy (NRT) approximately doubles the 
rate of smoking cessation from simple advice from GPs or more intensive clinic 
interventions (Silagy et al, 1997). These products replace some of the nicotine that 
smokers used to get from smoking. Nicotine replacement is used to wean smokers off 
nicotine by replacing the very high concentrations of nicotine obtained from cigarette 
smoking with much lower doses delivered more slowly. It is a means of delivering 
nicotine without the harmful tar, gases and other elements of smoking. NRT reduces 
the cravings for cigarettes and the withdrawal symptoms associated with quitting. 
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NRT is the most thoroughly researched method and tests have shown that, used 
correctly, it wil l double the chance of success. Nicofine replacement therapy appears 
to benefit those smokers who tend to light up within 30 minutes of waking 
(http://www.quit.org.uk). 
Some authorities advocate a harm reduction approach and suggest that nicotine 
replacement products could be given to heavily dependent smokers on a long term 
basis to reduce exposure to toxins and reduce morbidity and mortality (Russell, 1991; 
Warner et al, 1997). The justification for this approach is not that nicotine itself is 
harm free, but that in a pure form it is much less harmful than smoking (Russell, 
1974). There is a persuasive analogy which likens the cigarette to a dirty drug syringe 
and points to the potential benefits of a clean delivery system. Since smoking related 
diseases show clear evidence of dose and duration response, even partial and 
temporary reductions in total smoke exposure are likely to lower risk. On present 
evidence, nicotine from currently available pharmaceutical preparations does not pose 
a major threat to health (Benowitz & Gourlay, 1997). Nevertheless, there is an 
obvious need to study the effects of the long term use of NRT by persistent smokers 
and to establish the relationship between smoking reduction and reduced incidence of 
disease. 
Because the adverse effects of smoking in pregnancy are well known, many women 
stop smoking before or during pregnancy and active programmes to encourage and 
assist smoking cessation can achieve ftirther cessation. Unfortunately some of the 
heaviest smokers continue to smoke. Nicotine replacement therapy has not been 
evaluated in pregnancy because nicotine probably contributes to the deficit in birth 
weight in the babies of cigarette smokers (Olsen, 1992). However a review of the 
pharmacology of cigarette smoking and NRT has concluded that NRT results in lower 
plasma cotinine levels than heavy cigarette smoking, except during sleep (Benowitz, 
1991). The American Agency for health care Policy and Research (AHCPR) has 
suggested that NRT should be offered in pregnancy to heavy smokers. This is 
currently not advocated in the UK, but a research evaluation of such a programme 
should be undertaken (USDHHS, 1996). 
Nicotine replacement products that are FDA-approved include nicotine gum, 
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transdermal nicotine patches (TNPs), nicotine nasal spray, and nicotine inhaler 
(http://www.musc.edu/psychiatry/slater/smokel.htm). However, NRT is best viewed 
as a treatment adjunct rather than as a complete treatment in itself It will not help 
smokers who lack motivation to stop (http://vvfww.quit.org). 
2.1 Nicotine Gum 
In 1984 nicotine gum, Nicorette, became available in the United States as a 
prescription only medication. A box of 48 pieces costs approximately $30.00. In order 
to benefit from the gum, patients must use at least ten pieces of the gum per day. 
Patients who smoke fewer than 15 cigarettes per day should use the 2 mg dose while 
the 4 mg dose should be reserved for those who smoke more. The gum should be 
chewed slowly until a "peppery" taste appears in the mouth, and then "parked" 
between the gum and the cheek until the taste fades. Intermittent chewing and 
"parking" should continue for 30 minutes 
(http://www.musc.edu/psychiatry/slater/smoke 1 .htm). 
One of the disadvantages of the gum includes the special chewing techniques required 
as smokers might inadvertently forget. Smokers will also need to use the gum 
frequently. Adverse effects from the gum include jaw fatigue and soreness as well as 
gastrointestinal upset such as gaseous distension, hiccups, and nausea (Henningfield, 
1995). The gum is contraindicated for patients with gastric ulcers and is difficult for 
patients with dentures to use. Perhaps secondary to its demanding use requirements, 
nicotine gum has been shown to be more effective when used in specialised clinics 
than when used in general medicine practices. In a meta-analysis of randomized 
controlled trials, the success rates in specialised cessation clinics were significantly 
higher with nicotine gum than with placebo gum at 6 months (27%o vs 18%) and 
12 months (23% vs 13%i) (Capeda,1993). In contrast, success rates in general medical 
practices were no different with the gum and placebo (12%) at 6 months (Lam et al, 
1987).,Higher quit rates in specialised smoking cessation clinics may be a result of 
more in-depth counselling, better trained counsellors, and possibly smokers with 
"higher rnotivation to-quit" ^^"^^^^^  "^^^  
(Hftp:y/ww:tTfflsc:edix'p 
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2.2 Transdermal Nicotine Patches (TNPs) 
Three major brands of TNPs are Habitrol, Nicoderm CQ and Nicotrol. Patch brands 
differ in the rate control mechanisms, starting dose and weaning regimen. Patches are 
sold in 1-2 week boxes at a cost of approximately $30 per week, and initial therapy of 
some of the products include a cassette tape and a self-help booklet. The Habitrol and 
Nicoderm CQ patches are available as 21 mg, 14 mg and 7 mg for 6-8 week, 2-4 
week duration. The overall regimen for using these two patch brands is consistent: 
after approximately 1-2 months; patients switch to progressively lower dose patches 
until they are effectively weaned off the patch. Patients who smoke at least ten 
cigarettes per day can begin with the highest dose patch. The Nicotrol patch is a single 
dose patch of 15 mg and is intended for daytime use only as a 16-hour patch (i.e. it 
should be removed before going to sleep). Treatment is recommended for 6 weeks 
(http://www.musc.edu/psychiatry/slater/smokel.htm). 
Continuous controlled release of nicotine through a TNP resolves some of the 
problems associated with nicotine gum such as difficulty with use and side effects. 
Also, the potential for addiction to the medication is much lower by daily self-
administration of nicotine replacement with the patch than hourly replacement with 
the gam (Benowitz, 1988). A number of studies have shown the success of the TNP 
under controlled and real-world settings (Ahluwalia et al, 1998; Orleans et al, 1994; 
Silagy et al, 1994). The efficiency of the nicotine patch is reported to be about 20-
30% at six months. 
It is claimed that the main side effects of nicotine patches are itching or redness of the 
skin and this can be lessened by varying the position of the patch when users put a 
new one on. Some people who use the patch develop a mild skin rash on their body 
where the patch is placed. 
273 Nicotine Nasal Sprays 
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Nicotine nasal spray (Nicotrol nasal spray) is a relatively new product approved by 
FDA in 1996 for nicotine replacement delivery system. The spray is available only by 
prescription. It is designed to deliver nicotine more rapidly than the gum or patch, but 
less rapidly than smoking cigarettes (Schneider et al, 1996a). Users tend to self-
administer in order to produce plasma nicotine concentrations that are approximately 
50% of those achieved by smoking (Sutherland et al, 1992). The rapid delivery and 
relatively high plasma concentrations make the nasal spray more suitable for treating 
withdrawal symptoms and especially beneficial to highly dependent smokers. 
In a randomized controlled study, 32% of patients using the spray as prescribed were 
able to abstain from smoking 6 months after treatment, compared to 12% on the 
placebo. The rates at one year after quit dates were 26% and 10% for active and 
placebo sprays respectively. These findings suggest that the nicotine nasal spray is 
helpful in aiding smoking cessafion. 
The spray frequently irritates smokers' nose and throat for the first few days. The 
nasal spray may cause sneezing and a running nose (Quit, 1994). 
2.4 Nicotine Inhaler 
In 1998, the nicofine inhaler (Nicotrol Inhaler) became available as a prescription 
drug for smoking cessafion. It consists of a mouthpiece and a plastic cartridge 
designed to deliver 4 mg nicotine from a porous plug containing 10 mg nicotine. Most 
of the nicotine released from the inhaler is absorbed in the mouth, with less than 5% 
reaching the lower respiratory tract (Bergstorm et al, 1995). The nicofine inhaler also 
mimics the hand-to-mouth routine similar to cigarette smoking. It may therefore 
reduce the problems associated with abrupt cessation of the hand-to-mouth ritual. 
In a randomized controlled trial, individuals on active inhalers had continuous 
absfinence rates of 29% and 24% compared to 14% and 10% on placebo at 6 weeks 
and 3 months post-quit date respecfively (Schneider et al, 1996b). Other studies have 
reported similar findings (Leischow et al, 1996). The side effect is irritation of throat 
and mouth when people first start to use the inhaler. It might make the user cough. 
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In summary, the patch gives smokers a continual supply of nicotine at a low dose 
while smokers are wearing it - so smokers can't respond quickly to a craving or a 
stressful moment. The gum and the spray deliver a higher dose quickly so smokers 
can respond to a craving with a "quick fix", as with cigarettes. I f smokers smoke 
steadily through the day, the patch may suit them better. I f smokers smoke mainly in 
response to cravings or stress, the gum or spray might be more flexible for them. One 
study has compared the effectiveness of gum, patch, spray and inhalator and found 
that they were similarly effective (Quit, 1994). 
3 Non-nicotine drugs 
3.1 ZYBAN (bupropion hydrochloride SR) 
A number of non-nicotine products have been tested for smoking cessation, but only 
one has been approved by the FDA. Initially developed and marketed as an 
antidepressant under the trade name Wellbutrin, the sustained-release form was 
approved in 1997 as an aid for smoking cessation under a new trade name, Zyban. 
Bupropion is an alternative for smokers who either cannot tolerate nicotine 
replacement therapy or prefer non-nicotine treatment. In a randomized controlled trial 
(Hurt et al, 1997), 27% of patients who received the active drug were able to abstain 
from smoking 6 months after treatment compared to 16% of patients on placebo. Two 
months are needed to complete the treatment. 
Zyban is a non-nicotine treatment to help smokers who are motivated to quit. Zyban 
works in the brain to help break the addiction to nicotine and differs from nicotine 
replacement therapies in that it does not substitute one source of nicotine with 
another. Zyban reduces the cravings for cigarettes and the withdrawal symptoms 
.associated with quitting. Zyban comes in tablet form; it is taken as. a two month 
treatment course. The most common side,effects,are difficulty sleeping, dry mouth 
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and headache. These are usually mild and generally disappear within the first few 
weeks (http://www.quit.org). However, fifty-seven people have died after taking the 
anti-smoking drug Zyban (http://uk.news.yahoo.com/020117/80/cpnrf html). 
3.2 Other non-nicotine drugs 
There are many other non-nicotine drugs. There is not enough good scientific 
evidence to say how effective they are. One has to be wary of claims of very high 
success rates (http://www.quit.org). 
a) Name of Capsules 
Contains menthyl valerate, quinine, camphor and eucalyptus oil aimed at 
improving breathing and controlling withdrawal symptoms. The 
mcinufacturers recommend 1-2 per day for 28 days. There is no evidence of 
their long-term efficacy, but they are not thought to be harmful. Because of the 
herbal contents, pregnant women should not use them. 
b) Dummy cigarettes 
A plastic look-a-like that lasts between 1-3 months provides the hand-to-
mouth stimulation of smoking. They do not help with the physical withdrawal 
symptoms. They are of no proven benefit, but they are not shown to be 
harmful. It has been reported by ex-smokers as a means of working off 
symptoms of cigarettes (CHS, 1996). 
c) Herbal cigarettes 
Again these provide the activity of smoking without the nicotine, so they do 
not help with withdrawal symptoms. They still contain tar and poisonous 
carbon monoxide gas which are found in ordinary cigarettes and which cause 
considerable damage to health. The idea is that they claim to eliminate 
nicotine from the body whilst not challenging the behaviour of smoking. There 
is no proven evidence that these herbal cigarettes are effective. 
d) Filters 
Filters are designed to remove some of the tar and nicotine before the smoke is 
inhaled. Filters are attached to the end of an ordinary cigarette. Smokers tend 
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to compensate for the drop in nicotine by puffing longer and drawing harder or 
even covering up the filter to stop it working. They are meant to help smokers 
to adjust to less nicotine - but as with cutting down they have not been shown 
to work. 
e) Mouthwash 
Mouthwash is supposed to work by making cigarettes taste unpleasant. The 
product recommends you gargle with it for about 15 seconds whenever 
smokers feel a strong desire to smoke. It affects the taste of cigarettes for three 
to four hours, but it also adversely affects the taste of food for about half an 
hour. The product is not clinically proven. 
4. Combination drug therapy 
Although all the pharmaceutical products discussed above have been recommended 
for use as stand alone as single treatment, combination of treatments may be 
appropriate for smokers who are unable to quit with monotherapy. 
4.1 Combined use of Nicotine Replacement Products 
Given its acute delivery and, therefore, usefulness for acute cravings, some physicians 
began prescribing gum in conjunction with the TNPs. A review of four studies which 
documented statistical significance (Fagerstrom, 1994), concluded that for heavy 
smokers, combined use of 5-7 pieces per day of gum with the 16 or 24 hour TNP 
significantly reduced withdrawal symptoms and increases initial cessation rates more 
than use of either produce alone. Side effects were not significantly increased by 
combined use of nicotine patch and gum. A recent study (Blondal et al, 1999) also 
reported higher quit rates when the patch was combined with the nasal spray than with 
the patch alone (15% vs 35% at 6 weeks, 37%) vs 25% at 3 months for the 
combination and patch only respectively). Combined treatments should be considered 
for smokers with significant craving or withdrawal symptoms despite adequate doses 
of single agents. 
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4.2 Combined use of Transdermal Nicotine Patch and Bupropion 
A recent randomized controlled study compared bupropion and nicotine patch against 
treatment using both agents. The study concluded that abstinence rates were 
significantly higher in the subjects using bupropion and nicotine patch than the 
subjects using the patch alone. However, the difference in abstinence rates between 
the combined treatment and bupropion alone was not statistically significant (Jorenby 
et al, 1999). 
5. Diet and exercises therapy 
Both diet and exercise have an important effect on the smokers' body. Stopping 
smoking is a major change for the body to adapt to, and a healthy diet and regular 
exercise suitable to level of fitness, may help the body to cope with withdrawal and 
boost sense of self-confidence and well-being. There is now some evidence that 
regular light exercise can help people to stop smoking. For example, keeping busy to 
help take the mind off cigarettes, drinking plenty of fluids, getting more active -
walking instead of using the bus or car, changing routines. There is also a tendency 
for smokers either during the process of quitting or immediately after quitting, to 
compensate smoking by nibbling. Therefore, there is a danger for them to put on 
weight. Diet and exercises are also important to counteract adverse effects of giving 
up smoking (Quit, 1994). 
2.3.3 Traditional Chinese Medicine (TCM) to smoking cessation 
Traditional Chinese Medicine (TCM) has been used since the 8"^  century B.C. TCM 
can be used for promoting health as well as preventing and curing diseases. The 
theory behind TCM is that the body is a dynamic energy system. There are two types 
of energy - Yin and Yang. Yin represents the earth, cold, and femininity and Yang 
represents the sky, heat and masculinity. The interaction between Yin and Yang gives 
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rise to energy called "qi" which is transported throughout the body via meridians and 
collaterals. It is thought i f there is an imbalance in Yin and Yang then symptoms 
occur. TCM uses a number of treatment methods to restore the balance of Yin and 
Yang; these include herbal medicine, acupuncture, moxibustion, manual therapies, 
exercise, breathing techniques and diets. Surgery is rarely used. TCM, particularly the 
theory of meridians and collaterals is the most widely used traditional medicine. 
The meridians and collaterals are the pathways that carry qi, blood and body fluid and 
they can connect all parts of the human body. Al l the internal organs, apertures, skin, 
tendons, muscles, bones, hair and other tissues in the body are connected through the 
meridians and collaterals. Most meridians and collaterals have certain running routes. 
In physiology, the meridians and collaterals, qi, blood and body fluid are distributed 
around the body to play the roles of nourishing all parts of the human body. The 
functional activities of the meridians and collaterals are presented as the reactions and 
transmissions of them. In pathology, the external pathogens invade the human body 
from the body surface to the internal organs through the meridians and collaterals; 
while the dysfunction of the internal organs can affect the relative parts of the body 
through the meridians and collaterals. For example, in the case of cardiac pain, the 
pain may radiate to the ulnar side of the arm. Furthermore, diseases of the internal 
organs may also be reflected on certain parts of the body surface with tenderness, 
nodules, prominences, depression, congestion, etc. The reactions are often helpful in 
the diagnosis of the internal organ diseases. The therapies of acupuncture, 
moxibustion, massage. Qigong and some herbal medicine are all based on the theory 
of meridians and collaterals. They are practised in every region in the world. 
Additionally, there are certain acupoints along the meridians and collaterals. 
Acupoints are the specific sites in the skin where qi comes in and goes out from the 
body surface. They are related to the internal organs closely through meridians and 
collaterals. Acupoints can not only reflect the physical and pathological changes of 
the internal organs, but also receive various stimulations, such as herbal medicine, 
acupuncture, moxibustion massage, etc. It can regulate the functions of the internal 
organs and make Yin and Yang balanced in the human body for preventing and 
treating diseases when stimulating acupoints. 
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TCM has been used for thousands of years in the Far East, including acupuncture and 
herbal medicine (Cheung & Woof, 1994). Tobacco use has developed gradually in the 
past, one hundred years ago. There is relatively little evidence to demonstrate the 
effectiveness of TCM on smoking cessation. However, anecdotally, many people 
report that they found these treatments helpful. Up to now, it has been the most 
common method used to treat nicotine addiction, based on the theories of meridians 
and collaterals and herbal medicine. 
In 1981, a new acupoint for smoking cessation "Tim Mee" (Appendix A) was 
discovered by American Doctor James S. 01ms, and was used to stop cessation 
successfully (Tan, 1996). Where is it exactly? Tim Mee acupoint is located in the 
wrists of both hands. Along a horizontal line along the edge of the styloid process of 
radius and the side of short extensor muscle tendon of thumb close to the palm, as a 
vertical line. The intersection point of the two lines is Tim Mee acupoint 
(http://www.zhongmai.com). 
James S. 01ms reported he treated 5000 nicotine addicts by giving Tim Mee acupoints 
an acupuncture therapeutic method in 1981. He inserted the filiform needles into the 
Tim Mee acupoints of both hands accurately, leaving the needles in the acupoints for 
15 minutes. The general rate of effectiveness was 80%. In 1984, he reported he 
treated 2282 nicotine addicts by stimulating Tim Mee acupoint using a laser. The total 
rate of success was more than 90% (Tan, 1996). 
Ren X. (Ren, 1993) treated 61 nicotine addicts through needling Tim Mee acupoint 
with filiform needles. Firstly, he needled Tim Mee acupoints, and then the needles 
were cormected with electric-needle apparatus. Thirdly, the needles remained in the 
acupoint for 30 minutes. The treatment was carried out once a day or every other day, 
a course of treatment 3 times. 55.74% of smokers quit smoking 6 months after the 
treatment. 18.03% of smokers managed to reduce smoking per day to less than 2/3 of 
the previous amount, 6 months after the treatment. 
Yang H.O. (Zhou, 1997) treated 51 smokers by needling the Tim Mee acupoints. He 
needled the Tim Mee acupoints of both hands, the needles remained in the acupoints 
for 10 minutes per day, a course of treatment from 2 to 4 times. The rate of quitting 
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smoking was 98.04% at the end of the treatment. 
Xia M . (Zhou, 1997) treated 51 smokers by needling the Tim Mee acupoints. Tim 
Mee acupoints of both hands were stimulated strongly with filiform needles. 16 
(31.4%) smokers quit smoking completely; 20 (39.2%) managed to reduce their 
smoking to less than the previous amount and 15 (29.4%) failed to quit at the end of 
the treatment. 
Xu J. (Xu, 1997) worked in the Department of the Orient Medicine in Bastyr 
Medicine Institute and Freedom Acupuncture Clinic from July 1994 to May 1997. He 
treated 51 nicotine addicts by needling the Tim Mee acupoints, mainly. The treatment 
achieved "satisfied" therapeutic effectiveness. 17 males and 34 females aged from 19 
to 55 joined the study. Their years of smoking experiences were 1-40 years and the 
average smoking experience was 8.3 years. The Tim Mee acupoints of both hands 
were needled first, and then the needles remained in the acupoints for 25 minutes. The 
treatment was carried out every other day, a course of six treatments. 66.67% of 
smokers quit smoking and 17.65% managed to reduce smoking per day less than 2/3 
of the previous amount 6 months after the treatment. 
Peng X. (Peng, 1984) treated 126 nicotine addicts using "skin applied plaster instead 
of acupuncture". There were two herbal ingredients - Clovers and Cassis - in the 
plaster. He applied the plasters on the skin where Tim Mee acupoints of both hands 
were located. The plasters were applied for 24 hours. Patients smoked one cigarette 
after applying the plasters for 15 minutes. It was found that 65.1% of smokers at the 
taste of smoking became pale, dizzy and nauseous. The rate of total effectiveness was 
88.9%. 
Tim Mee (Zhou, 1997) is an effective acupoint for smoking cessation. It is the most 
sensitive point of human body when someone is addicted to smoking, and is the 
effective acupoint to be stimulated to stop smoking. Many doctors found the taste 
sensation of smokers changed when they smoked again after the Tim Mee acupoints 
were stimulated. They thought this kind of change was based on some substance in 
the human body which had changed. Many scholars thought the reason for smoking 
addiction was that "internal opium" was restrained to excrete, a lack of this after 
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"external opium" was absorbed by the body, caused dependency for "external opium" 
substances, such as nicotine. The production of "internal opium" in the brain after 
stimulating Tim Mee acupoints, reduced the dependency for "external opium" 
substances. 
More recently, a number of prepared herbal medicines for smoking cessation were 
launched, based on the theories of TCM on meridians and collaterals and herbal 
medicine, such as Zhong Mai Yan Ke. This herbal preparation conquered the 
disadvantages of acupuncture treatment. It utilizes various Chinese herbs and 
biological magneto-therapy, acts on Tim Mee acupoint on the wrists of both hands, 
reportedly stimulates taste, sense and nerve system of the human body and changes 
the smell of cigarette smoking, so as to encourage smoking cessation. Zhong Mai Yan 
Ke contains the following main active ingredients: 
(1) Cloves: It contains clove oil whose primary material is clove-phenol. This is a 
fragrant pharmaceutical which can be used particularly for alleviating 
abdominal discomfort and vomiting, regulating digestion and promoting 
appetite. Clove-phenol in Zhong Mai Yan Ke can reportedly influence the 
fiinction of stomach and intestines and improve constipation often caused by 
long-term smoking. Additionally, clove-phenol can influence to inhibit cramps 
caused by tobacco-alkali during the course of quitting smoking. 
(2) Cassia: Cassia contains cassia bark oil and cassia bark aldehyde which is 
found in fragrant elements in them. Cassia bark aldehyde can stimulate natural 
endorphins within the brain to relieve irritation and reduce cramps caused by 
strong tobacco-alkali. It has been commented that the absorption for cassia 
bark aldehyde can prolong the time of patches' adherence. Cassia bark 
aldehyde in Zhong Mai Yan Ke ensures that the active ingredients reach 
meridians and collaterals completely through Tim Mee acupoint where Zhong 
Mai Yan Ke applies. Cassia in Zhong Mai Yan Ke can improve the harmful 
effects caused by tobacco-related toxins and plays a role to substitute 
acupuncture treatment. 
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(3) Areca: Areca contains areca alkali, nutmeg and areca oil. Areca can regulate 
the function of central nervous system through improving the functions of 
stomach, intestines, lungs and bronchus, expanding blood vessels and 
stimulating N-choline receptors, skeletal muscle and neuromere. It can 
stimulate the brain to produce endorphins to reduce pain and irritability caused 
by nicotine withdrawal during the course of quitting smoking. Present research 
indicates that smokers' tobacco cravings are interrelated to the stimulation for 
endorphin central nervous system. Thus Areca in Zhong Mai Yan Ke can 
influence the brain to produce endorphin to adapt the physiological 
uncomfortable feeling caused by quitting smoking. Furthermore, it also 
stimulates the central nervous system to promote easier relief from symptoms 
caused by tobacco withdrawal. Reports indicate that areca-alkali and areca-
tannin can suppress the desire for tobacco and restore appetite at the same 
time. 
(4) Magnetic disc: From the perspective of biological polarity, the human body is 
a charged entity and capable of electric conduction. Different organs and 
tissues have different electrical activity. The functions of organs and tissues 
can be affected when an external magnetic field acts upon the human body 
continuously. The theory behind the use of magnetic discs is that magnetism 
produced by a low magnetic field is sufficient to adjust people's desire. The 
magnetic disc (approx. 400 gauss) in Zhong Mai Yan Ke is combined with 
herbal ointments which act upon Tim Mee acupoint simultaneously to 
strengthen the transmission ftmction of meridians and collaterals so that drug 
ions within the herbal ointment are absorbed easier and pass through the skin 
more rapidly, thus the active ingredients in the medicine are more effective. 
It is claimed that the rate of effecfiveness (quitting completely and reducing cigarettes 
per day) of Zhong Mai Yan Ke for smoking cessation is 85% and has no serious side 
effects. However, there is no feasibility study to prove that herbal preparations are 
efficacious. It is necessary to ascertain the extent of the effect of Zhong Mai Yan Ke 
(http://zhongmai.com). 
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2.4 Summary 
Nicotine addiction is the main problem preventing smokers from quitting 
successfully. Many smoking cessation approaches have been tried in the world. Social 
and health education, advice and encouragement and some products, especially 
Nicotine Replacement Therapy (NRT), are used widely in the West. Traditional 
Chinese Medicine, particularly acupuncture has been used to treat smoking cessation 
in China and other countries because a new acupoint - Tim Mee - for smoking 
cessation was found in recent years. The therapeutic effect of needling Tim Mee 
acupoint is effective, but it is not stable because it is limited by the acupuncture 
techniques. Moreover, it is not a hugely convenient approach. In the last few years, it 
has been claimed that Zhong Mai Yan Ke, a Chinese herbal preparation for smoking 
cessation has achieved good therapeutic effect in China. However, it is necessary to 
ascertain the true extent of the effect of Zhong Mai Yan Ke through research. 
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Chapter 3 
Aims and Methodology 
3.1 Introduction 
New research should be encouraged in smoking cessation using different approaches 
and other products which are not previously known through research and publications. 
A herbal preparation "Zhong Mai Yan Ke (Joymain Nicofree)" which was invented 
according to the theories of Traditional Chinese Medicine (TCM) was introduced for 
smoking cessation and it has been claimed by the manufacturer that the effective rate 
of Zhong Mai Yan Ke on smoking cessation is 85% after 9 days or 18 days of 
treatment (http://zhongmai.com). However, such a claim carmot be substantiated as 
there has been no systematic investigation of the substance used. 
My chief aspiration was to attempt to determine the extent of the effect of nine days 
application of Zhong Mai Yan Ke and the effect at three months. Zhong Mai Yan Ke 
is a commonly used, commercially easily available product in China and over one 
million smokers in China have purchased the product. Like many other herbal 
remedies in China, its effect has never been formally evaluated, even though it has 
been available widely in public for a long time. I f the product is shown to be effective 
to help smokers to quit, it could help many smokers throughout the world. As a 
preliminary it is necessary to do a therapeutic trial for detailed research on Zhong Mai 
^ a n K e . 
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The study had the following objectives: 
(1) To ascertain the effect of Zhong Mai Yan Ke through an open randomised 
trial in a pragmatic setting in China at the end of a 9 day trial, based on 
whether at least 30% of the smokers in the treatment group would be able to 
reduce the number of cigarettes smoked per day, (b) at least 20% will be able 
to give up the habit completely and i f at the 9-day trial (c) 3 months, at least 
20% of the smokers in the treatment group would be able to reduce the number 
of cigarettes smoked per day and at least 10% would be able to give up the 
habit completely. 
(2) I f smokers in the treatment group experienced effects as indicated by the 
manufacturer of Zhong Mai Yan Ke. 
(3) To ascertain the feasibility of organising an open label randomised 
controlled trial and confirming the acceptability of the use of placebo in the 
cultural and commercial setting of China. 
3.2 Research approach: Randomised controlled trials 
The most appropriate approach for evaluating pharmacological intervention is the 
application of methodology used for experimental studies. Most experimental studies 
use randomised controlled design because the intention of the research is to influence 
events and ascertain the effects of the treatment. Randomised controlled trials are 
widely used in medical research. The aim of the randomised control design is to 
ensure that differences between individuals, other than the method of treatment, being 
evaluated are distributed evenly by chance between two groups. Such an application 
was considered suitable to evaluate the treatment effects produced by Zhong Mai Yan 
>Ke as a smoking cessation agent, but there were a number of constraints to this. 
Randomisation also serves the important purpose of allocating tfeafrnenfs to patients 
free from the researcher's biases. It also provides a basis for the application of 
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significant tests likely to be used to assure treatment effects. 
(http://www.bmjpg.com/rct/chapterl.html) 
Typically, RCTs seek to measure and compare events (outcomes) that are present or 
absent after the participants receive the interventions. As the outcomes are quantified 
(or measured), RCTs are regarded as quantitative studies. RCTs are referred to as 
randomised controlled trials because one of the interventions is regarded as a standard 
of comparison or control. The control can be conventional practice, a placebo, or no 
intervention at all. RCTs are experiments because the investigators can influence the 
number and the type of interventions, as well as the regimen (amount, route and 
frequency) with which the interventions are applied to the participants. 
(http://www.bmjpg.com/rct/chapterl.html). 
In summary, RCTs are quantitative, comparative, controlled experiments in which a 
group of investigators who design the study, administer the interventions, assess the 
results and analyse them. The studies involve two or more interventions in a series of 
individuals who receive them in random order. 
(http://www.bmjpg.com/rct/chapterl.html). 
3.3 Open randomised controlled trial 
Randomised clinical trials (RCTs) can be used to evaluate different types of 
interventions in different populations of participants, in different settings, and for 
different purposes. Once investigators ensure that allocation of participants to the 
study groups is random, they can design the study using strategies to match the 
characteristics of the interventions they want to study, the resources they have 
available, and their academic, political, marketing, or clinical motivations. 
(http://www.bmjpg.com/rct/chapterl .html). 
"There is empirical evidence confirming that the effects of new interventions can be 
exaggerated i f the raJndorhisation sequence is not concealed from the investigators at 
the time of obtaining consent from prospective trial participants (Chalmers et al, 1983; 
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Schulz, 1995). One study showed that trials with inadequate allocation concealment 
can exaggerate the effects of interventions by as much as 40% on average (Schulz, 
1995)." (http://www.bmjpg.com/rct/chapter3.html). That means allocation 
concealment helps to prevent selection bias and protects the randomisation sequence 
before and until the interventions are given to study participants. 
In a RCT, random allocation is an important part that could influence the outcome of 
the experiment. Random allocation means that all participants have the same chance 
of being assigned to each of the study groups (Altman, 1991). Random allocation of 
the participants to different study groups increases the potential of a study to be free 
of bias (http://www.bmjpg.com/rct/chapter3.html). Therefore, allocation is not 
determined by the investigators, the clinicians, or the study participants. 
By allocating the participants randomly, the characteristics of the participants are 
likely to be similar across groups at the start of the comparison (also called the 
baseline). By keeping the groups as similar as possible at the start of the study, the 
investigators will be more able to isolate and quantify the impact of the interventions 
that they are studying, with minimal effects from other factors that could influence the 
course of the study participants. The factors that could influence the outcomes of a 
study, which are not related directly to the interventions, could be known or unknown. 
(http://www.bmjpg.com/rct/chapterl.html). 
The generation of random sequences of allocation can be achieved using one of a 
variety of procedures, such as flipping a coin or rolling a dice, using number tables or 
a computer. The trial used the method of drawing out randomly. 
Sometimes investigators feel it is not necessary to make the number of participants in 
each of the study groups the same and can decide to allocate unequal numbers to each 
group, when they are preserving the homogeneity of the distribution of the 
characteristics of the participants across the study groups. This is called unequal 
randomisation (http://www.bmjpg.com/rct/chapterl.html) or "weighted 
randomisation". The trial in this study used unequal randomisation. The investigator 
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took one month to recruit the volunteers. The poster had been posted up to the 
window of the medicine shop for one month. The investigator screened 75 volunteers 
recruited through advertisements. At the deadline of the recruitment, 64 smokers were 
selected to participate in the trial according to their healthy condition and smoking 
status (see 3.4.2). Nutralife Company has provided 50 boxes of Zhong Mai Yan Ke, 
so the investigator decided to allocate 50 volunteers in the treatment group to receive 
Zhong Mai Yan Ke - Chinese herbal patches, whereas the other 14 volunteers in the 
other group received placebo patches. Band-aid super-elastic adhesive bandage, 
which resembles the appearance of Zhong Mai Yan Ke. Applying the Fisher exact 
test, the findings of the trial is found to be of statistical significance. It is explained in 
chapter 4 one by one. 
The investigator in charge of recruiting volunteers for this trial recruited the 
volunteers based strictly on the inclusion and exclusion criteria. That is to say the 
volunteers who did not meet the inclusion criteria or meet exclusion criteria were 
excluded from the trial. Of the 75 volunteers, 64 of them were selected to participate 
in the trial. The randomisation sequence was concealed at the time of obtaining 
consent from prospective trial volunteers and until the interventions were given to 
them. The volunteers did not know which intervention, Zhong Mai Yan Ke or 
placebo, would be provided to them until they had actually received it. 
Depending on the extent to which the participants are exposed to the study 
interventions, RCTs can have parallel, crossover, or factorial designs. Most RCTs 
have a parallel design. In these studies, each group of participants is exposed to only 
one of the study interventions (http://wvvfw.bmjpg.com/rct/chapter2.html). In the trial, 
the researcher used a parallel design to evaluate the effects of Zhong Mai Yan Ke 
compared with those of a placebo in participants. 
Depending on the extent of blinding, RCTs can be classified as open, single-blind, 
double-blind, triple-blind, and quadruple-blind. The trial was designed as an open 
randomised controlled trial (RCT). An open RCT is a randomised trial in which those 
_involved_in the trial know which intervention is given to each participant 
. (http://w>^.bmjpg.corn/rctychapter2.html ). In the trial, the volunteers in the 
39 
treatment and control groups knew the identity of the interventions, Zhong Mai Yan 
Ke or placebo when they applied them because Zhong Mai Yan Ke is an approved 
medicine in China and they were given to the volunteers in the treatment group in 
sealed boxes designed by the manufacturer. The employed medicine shop keeper who 
administered the interventions and the researcher, who assessed the outcomes of the 
interventions, analysed the data and wrote the results of the trial, also knew the 
identity of the interventions. 
3.4 Study design 
3.4.1 Background 
The trial investigated the extent of the effect of Zhong Mai Yan Ke as compared with 
placebo. The trial was completed in China because Zhong Mai Yan Ke and the 
placebo are legally licensed medicine only in China. Zhong Mai Yan Ke (No. 126006) 
was registered in official trade documents by Jiangsu Province Medicine and Medical 
Apparatus Controlling Station in 1998 in China and was available for purchase in 
1998 in China. The placebo - Band-aid super-elastic adhesive bandage are products of 
the Johnson Company. There is no medication in the bandages. 
Although the placebo - Band-aid super-elastic adhesive bandage has a very similar 
appearance and size, it was impossible to design the trial as a blinded one. The study 
had to be designed on a feasibility basis for the following reasons: 
(1) ZYMK, legally licensed, is commonly known and available in China. It was not 
possible to alter the packaging or its presentation to make it appear completely similar 
to a placebo. It was inevitable thus that the participants would know which item they 
had been given. 
(2) ZMYK was extensively advertised on TV, radio, newspaper, etc and was a well-
known smoking cessation product. It's TV advertisement showed detailed instrucfion 
of how the product was applied. Many people, including smokers, knew there was a 
magnetic disc in the patch of ZMYK. However, Band-aid adhesive bandage included 
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no such magnetic discs in its patch. That meant that the volunteers always knew i f the 
product they used was ZMYK by checking i f a disc was in it. 
Nutralife Company agreed to provide 50 boxes of Zhong Mai Yan Ke for the study. 
The "placebo" was purchased by the researcher and the researcher paid £200 to 
employ a medicine shop keeper to recruit the volunteers, administer the interventions 
and to collect data. 
3.4.2 Recruitment 
Healthy adult volunteers who were smokers were recruited from the city of Dalian in 
China. The investigator had put up a poster recruiting volunteers in the window of the 
shop for one month (Appendix Bi). During one month's recruiting, the investigator 
screened 75 volunteers recruited through these advertisements. They were asked to 
come to the medicine shop. The volunteers were given a health screening 
questionnaire (Appendix B 2 ) and their smoking status was recorded (Appendix B3). 
Sixty four volunteers were recruited based on the inclusion and exclusion criteria as 
mentioned below. Informed consent (Appendix B3) and volunteer instruction leaflets 
(Appendix C) were used. Volunteers could withdraw from the study at any time. The 
proportion of male and female volunteers in this study is representative of the 
proportion of males and females in the smoking population. 
Current cigarette smokers have been fiirther sub-divided by the reported number of 
cigarettes smoked per day. Smokers are grouped into three categories. Light smokers 
are those who reported smoking under 10 a day, moderate smokers are those who 
reported smoking 10 to less than 20 a day, and heavy smokers are those reported 
smoking 20 or more a day (http://www.official-
documents.co.uk/document/deps/doh/surveyO 1 /fvc/fvc-08.htm). 
The volunteers were selected based on the following criteria: 
• 18 years of age or older 
„ • moderate and heavy smokers who smoke rnpre than 10 cigarettes a day 
• Motivation to quit was high 
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• Dextrous in applying Zhong Mai Yan Ke patches and placebo plasters 
• Could follow instructions carefully 
The volunteers were not selected based on the following criteria: 
• pregnant women 
• anyone with hypersensitivity to patches 
• anyone with serious illness and receiving medication or herbal treatment 
3.4.3 Random allocation 
The generation of random sequences of allocation can be achieved using one of a 
variety of procedures. The trial uses the method of drawing out to generate random 
sequences of allocation. Firstly, the investigator numbered the 64 selected volunteers 
randomly. These scripts were folded and the numbers concealed. Thirdly, the 64 
scripts were mixed. Fourthly, 14 scripts were drawn out. These 14 scripts were 
allocated to placebo and the other 50 scripts to Zhong Mai Yan Ke. 
3.4.4 Intervention 
As discussed in section 3.3, an open randomisation approach was used. Therefore, the 
subjects in both groups knew the substance they were given. The smokers in treatment 
groups were given one box of Zhong Mai Yan Ke and those in control groups were 
given placebo. Similar written instructions on the application of patches were given to 
both groups. 
• The treatment group: 
50 participants were given a supply of one box of Zhong Mai Yan Ke - 18 
patches, sufficient for the 9 day trial. They were asked to apply a patch once a 
day to each wrist at the acupoint of Tim Mee (Appendix A & Appendix C) and 
left m place for 22 hours, then remove the patches and apply a new patch to 
each wrist ^fter 2 hours. The course of treatment was for 9 days. 
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• The control group: 
14 participants were given placebo - 18 pieces of Band-aid super-elastic 
adhesive bandage which has a similar appearance to Zhong Mai Yan Ke. This 
kind of bandage can be bought in any medicine shop in China. The participants 
were asked to apply the placebo once a day to each wrist at the acupoint of 
Tim Mee and left in place for 22 hours then remove them and reapply a new 
patch to each wrist after 2 hours. The course of treatment was for 9 days. 
3.4.5 Data Collection 
The trial was conducted in Dalian City, China and the researcher was responsible for 
the selection of a medicine shop for the research. An investigator was also appointed 
by the researcher to oversee the conduct of the research, responsible particularly for 
the initial data collection and for the three month follow-up data collection. The health 
screening (Appendix Bi) and smoking status questionnaire (Appendix B3) were 
collected immediately when the volunteers agreed to join the trial in the medicine 
shop. The smoking status questionnaire was repeated to both treatment and control 
groups at the end of the 9 day trial. The data sheet was designed by the researcher and 
was translated into Chinese by the researcher herself Al l data were recorded in 
Chinese by the appointed investigator, and then translated into English by the 
researcher. The data sets in English are presented in the appendix (Appendix D). 
Al l subjects were followed up three months after the trial using a telephone interview 
technique. The telephone interviews were conducted using some of the questions in 
the smoking status questionnaire, e.g. 
Are you still a smoker? 
I f yes, how many cigarettes do you smoke a day? 
Did you have any unpleasant reactions while wearing the patches? 
I f yes, please give the details. 
3.4.6 Data Analysis 
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The data analysis was performed wi th the help o f a professional statistician f rom the 
department o f mathematical sciences at the University o f Durham. Chi-square test or 
Fisher's exact test was used in analysis. 
3.4.7 Ethics 
In China there is no conventional ethics committee structure as in the U K . However, 
all the steps required for such a study were adhered to - i.e. recruitment o f volunteers, 
informed consent and the ability o f the participants to withdraw at any stage. 
Furthermore the following factors were considered: 
(1) Zhong Mai Yan Ke and the placebo Band-aid adhesive bandages are all legally 
licensed products and have been available widely for a long time and are relatively 
well known to the public. 
(2) They are readily available without a prescription. 
(3) It has attained acceptance as a well known product; Zhong Mai Yan Ke is known 
to contain a herbal remedy. 
(4) Zhong Mai Yan Ke and placebo are not associated with any known or worrying 
side effects. 
(5) The researcher sought advice and received a letter f rom the Institute o f 
Pharmacology at the School o f Medicine, Dalian University, in which Professor Xie, 
Director o f the Institute o f Pharmacology, confirmed that the methodology used in this 
therapeutic trial was appropriate, without ethical concerns in China (Appendix E). 
3.5 Limitations 
I t has been argued by researchers and manufacturers o f herbal products in the U K that 
the acceptability o f research findings is partly dependent on the location where the 
study was conducted. For example", studies conducted outside the U K , EU of the US A 
may be regarded with some suspicion. The researcher is aware o f this argument. This 
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study was an attempt to apply recognised western research methods to ascertain the 
effects o f a potential treatment for smoking cessation. The researcher does not believe 
that the pharmacological effects o f nicotine differ greatly, i f at all, amongst the human 
race irrespective o f the country o f origin. Therefore, the findings in the East, provided 
that the protocols used could be replicated, could be applied to the West. 
The researcher could have employed a double-blind trial as an additional safeguard. 
However, only an open randomised trial was possible in a commercial setting in 
China within that very specific cultural setting. In fact, one could prolong the 
discussions on the relative merits o f various research methodologies used in medical 
investigation. Randomised controlled trials advocated by the west are not without 
problems. RCTs are vulnerable to multiple types o f bias at all stages o f their lifespan. 
In health care research, bias is defined as any factor or process that tends to deviate 
the results or conclusions o f a trial systematically away from the truth. This deviation 
f rom the truth can result in underestimation or exaggeration o f the effects o f an 
intervention. The main reason to anticipate, detect, quantify, and control bias is that 
the true effects o f any health care intervention are unknown. The purpose o f RCTs, as 
well as any other study or research enquiry, is to produce results f rom a sample o f 
participants that could be generalised to the target population at large. It is impossible 
ever to know for sure whether the results o f a study are biased, simply because it is 
impossible to establish whether such results depart systematically f rom a truth that is 
unknown. Despite this major limitation, many possible sources o f biases have been 
recognised over the years. The existence o f most o f these biases is supported mainly 
by common sense. Some biases can occur at any point during the course o f a trial. 
Other biases can occur during the dissemination o f a trial f rom the investigators to 
potential users, or during the uptake o f trial information by potential users o f the trial 
(http://www.bmjpg.com/rct/chapter3.htm). 
For example, one bias occurs when the results or conclusions o f a trial are 
systematically distorted by knowledge o f which intervention each participant is 
receiving. The best way to protect a trial against this kind o f bias is by keeping the 
people involved in the trial unaware o f the identity o f the interventions for as long as 
possible (http://www.bmjpg.com/rct/chapter3.html). However, the trial was designed 
45 
as an open trial. A l l participants in the study knew the identity o f the interventions. So 
this bias may occur under this circumstance. 
The other bias was introduced by drop outs. Ideally, all participants in a trial should 
complete the study, fo l low the protocol, and provide data on all the outcomes o f 
interest at all time-points. In reality, however, most trials have missing data. Data can 
be missing because some of the participants drop out before the end o f the trial, 
because participants do not fol low the protocol either deliberately or accidentally, or 
because some outcomes are not measured correctly or cannot be measured at all at 
one or more time-points. Regardless o f the cause, inappropriate handling o f the 
missing information can lead to bias (http://www.bmjpg.com/rct/chapter3.html). In 
the trial, only one participant who was allocated to Zhong Mai Yan Ke did not 
complete the study due to business, when he missed the first 9-day treatment course. 
3.6 Summary 
A n open randomised controlled trial was considered appropriate to evaluate the 
effectiveness o f Zhong Mai Yan Ke in a commercial setting in China within that very 
special cultural envirormient. When designing the study, the researcher has 
considered about the bias that can occur in the trial. As a fu l ly blinded randomised 
controlled trial was not possible it was considered that this open trial would provide 
data on the feasibility o f a study in this setting and pilot data on the possible 
effectiveness o f the product. This has been accomplished within this limited project. 
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Chapter 4 
Clinical Trial of Zhong Mai Yan Ke 
(ZMYK) 
4.1 Introduction 
The study consisted o f three phases: a screen/baseline phase, a 9 day treatment phase, 
and a three month follow-up phase. This chapter presents the main findings o f the 
clinical trial in China using Zhong Mai Yan Ke herbal patches involving 50 
volunteers in the treatment group and 14 volunteers in the control group. These 64 
volunteers were declared in their self-administered health screening questionnaire to 
be healthy. The smokers in the treatment groups were given a course o f Chinese 
herbal Zhong Mai Yan Ke treatment for 9 days, whereas the smokers in the control 
group were given placebo for 9 days. 
4.2 Findings 
4.2.1 Demographic Data and Baseline Characteristics 
1. Gender, age, length o f smoking experience, the level o f addiction and the No. o f 
unsuccessful attempts at quitting distribution 
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50 smokers o f the 64 volunteers recruited were randomly allocated to the treatment 
group and the remaining 14 to the control group. A l l the smokers in the treatment 
group were men whereas in the control group 13 were men and 1 was a woman. A l l 
smokers conformed to the inclusion and exclusion criteria as discussed in chapter 3. 
A l l except one in the treatment group successfully completed the trial. 1 person in the 
treatment group was excluded from the analysis as he failed to apply the patches 
correctly; therefore, he was excluded f rom the trial. Smokers' personal data and 
smoking characteristics are presented in table 4.1. 
Table 4.1 personal data and characteristics of smokers 
N 
gender 
Minimum Maximum Mean Std. 
Deviation 
Male 
(No.) 
female 
(No.) 
treatment 
group 
Age (years) 49 
49 0 
21 72 36.41 13.53 
Number of 
years smoked 
49 2 40 14.27 11.38 
Number of 
cigarettes 
49 12 40 24.41 8.64 
control 
group 
Age (years) 14 
13 1 
25 76 42.29 13.26 
Number of 
years smoked 
14 7 34 17.43 8,47 
Number of 
cigarettes 
14 12 38 23.21 8.13 
As shown in table 4.1 , a total o f 63 cigarette smokers were enrolled in the trial. Just 
98.4% (n=62) were male. There are large variations in the age, length o f smoking 
experience and the level o f addiction, i.e. no. o f cigarettes smoked per day, amongst 
the volunteers in both groups. However, there are no significant differences seen in 
these variables between the treatment and control group. For example, the mean age 
was 36.41 (SD±13.53) years (range, 21 to 72 years) in the treatment group and 42.29 
(SD±13.26) years (range, 25 to 76 years). Volunteers enrolled in this trial had smoked 
an average o f 24.41 (SD± 8.64) cigarettes per day at present (range, 12 to 40) in the 
treatment groups and 23.21 (SD±8.123) cigarettes (range, 12 to 38) in the control 
group. They had smoked for an average o f 14.27 (SD±11.38) years (range, 2 to 40) in 
the treatment group and 17.43 (SD±8.47) years (range, 7 to 34) in the control group. 
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It is also noted that, 83.7% (n=41) o f the smokers in the treatment group had not tried 
stopping smoking before the trial and 16.3% (n=8) o f them had tried to stop smoking 
unsuccessfully one or more times. A l l the smokers in the control group had not tried 
stopping stop smoking before the trial. 
2. The relationship between age, years o f smoking and degree o f addiction, i.e. No. o f 
cigarettes smoked per day. 
It is found that there are certain relationships between the smokers' age, length o f 
smoking experience and the level o f addiction in both groups. The relationship o f their 
variables can be observed f rom tables 4.2, 4.3, and 4.4 and figures 4.1, 4.2 and 4.3. It 
is found there is no difference in status o f smokers between treatment group and 
control group at the beginning o f the trial. It also shows whether the placebo is 
effective or not, it was not due to other differences in critical determinants o f the 
likelihood o f success for smoking cessation. Those smokers in both groups who were 
older had smoked for many more years than the younger smokers and tended to smoke 
more heavily. However, this observation really reflects the natural path o f nicotine 
addiction, in that, the older the smoker is, the more years he/she would have spent 
smoking and the degree o f addiction would correlate wi th age (Cheung & Woof, 
2001). 
Table 4.2 Relation between age and years of smoking 
groups of years of smoking total 
10 years 
or less 
11 to 20 
/ears 
21 to 30 
years 
over 30 
/ears 
age groups 
treatment group 
(underlined) 
control group 
(bold) 
20 to 30 
/ears old 
22 
3 
22 
3 
31 to 40 
/ears old 
3 
0 
8 
2 
11 
2 
41 to 50 
/ears old 
2 
3 
B 
4 
8 
7 
51 to 60 
/ears old 
1 
0 
4 
1 
5 
1 
Over 60. 
/ears old 
D 
T 
3. 
0 
3 
1 
Total 25 4 
10 
5 
7 
4 
7 
1 . _ 
49 
14 
49 
Figure 4.1 Relation between age and years of smoking 
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Table 4.3 Relation between age and degree of addiction 
groups of degree of smoking total 
10 to 20 21 to 30 over 31 
cigarettes cigarettes cigarettes 
age groups 
20 to 30 
years old 
20 
3 
2 
0 
22 
3 
treatment group 
(underlined) 
control group 
(bold) 
31 to 40 
years old 
4 
1 
7 
1 
11 
2 
41 to 50 
years old 
O
l T—
 
3 
5 
5 
1 
8 
7 
51 to 60 2 3 5 
years old 0 1 1 
over 60 0 3 3 
years old 1 0 1 
total 24 14 11 49 „6 - 6 2 14 
50 
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JO 
E 
3 
Figure 4.2 Relation between age and degree of addiction 
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Table 4.4 Relation between years of smoking and degree of addiction 
groups of degree of smoking 
total 
10 to 20 
cigarettes 
21 to 30 
cigarettes 
over 31 
cigarettes 
/ears of smoking 
treatment group 
(underlined) 
10 years 
or less 
22 
4 
3 
0 
25 
4 
11 to 20 
/ears 
2 
2 
7 
3 
1 
0 
10 
5 
control group 
(bold) 
21 to 30 
/ears 
2 
3 
5 
1 
7 
4 
over 30 
/ears 
2 
0 
5 
1 
7 
1 
total 24 6 
14 
B. 
11 
2 
49 
14 
51 
Figure 4.3 Relation between years of smoking and degree of addiction 
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4.2.2Effectiveness of Zhong Mai Y a n K e 
1. At the end o f the 9-day trial 
The smokers in the treatment group were given a supply o f herbal Zhong Mai Yan Ke 
patches for 9 days together wi th an instruction leaflet (Appendix B) giving details o f 
the trial and where the 2 patches should be applied every day for 9 days. The smokers 
in the control group received 2 placebo patches per day each for 9 days. 
It is found that all 14 smokers (100%) in the control group have failed to quit. 
However, amongst the 49 smokers in the treatment group, 7 smokers have failed to 
quit; however, 42 smokers have managed, either to give up their habit completely or 
reduce their daily smoking consumption. The overall effective rate is therefore 85.7% 
as shown in figure 4.4. Applying the Fisher exact test, the overall effectiveness o f 
Zhong Mai Yan Ke is found to be o f statistical highly significance with a p-
value<0.00\. 
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Figure 4.4 Percentage of people in the treatment and control group managed to change 
their smoking habit at the end of the 9-day trial 
Two groups in the trial 
effect no effect 
Effect of method 
• treatment group 
• control group 
When the overall effectiveness rate is to be broken down into those who have 
managed to quit successfully and those who have not but nonetheless have reduced 
their daily consumption, then the effectiveness o f Zhong Mai Yan Ke as a smoking 
cessation agent is shown to be highly significant. . 
Figure 4.5 Treatment effect at the end of the 9-day trial 
60 
50 
40 
30 
20 
no effect partial reduction quit smoking 
Effect 
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As shown in Figure 4.5, at the end of the 9-day trial, 5 1 % (n=25) in the treatment 
group managed to stop smoking completely while 35% (n=17) were able to reduce the 
number o f cigarettes daily. However there was no effect at all in 14.3% (n=7) o f the 
subjects o f treated group. Among those who reduced the number o f cigarettes smoked 
per day, 5 cases (10.2%) smoked less than 1/3 o f previous, 7 cases (14.3%) smoked 
between 1/3 andl/2 o f the number at Day 9, 5 cases (10.2%) smoked more than V2 o f 
the number at Day 9 and 7 cases (14.3%) had no effect after the trial. In the control 
group, all cases who applied placebo had no effect on smoking cessation (table 4.5). 
Table 4.5 Pattern of degree of addiction on Day 9 of trial in active ingredient and control 
group 
treatment groups 
total active 
ingredient 
group 
control 
group 
effect 
groups 
no change in smoking 
habit 
7 
(14.3%) 
14 
(100.0%) 
21 
(33.3%) 
smokes more than 1/2 of 
the number at Day 9 
5 
(10.2%) 
0 
(0%) 
2 
(3.2%) 
smokes between 1/3 and 
1/2 of the number at 
Day 9 
7 
(14.3%) 
0 
(0%) 
4 
(6.3%) 
smokes but less than 1/3 
of the number at Day 9 
5 
(10.2%) 
0 
(0%) 
11 
(17.5%) 
quit smoking 25 (51.0%) 
0 
(0%) 
25 
(39.7%) 
total 49 
(100.0%) 
14 
(100.0%) 
63 
(100.0%) 
2. Three months after the trial 
The smokers in both the treatment and control group were followed-up three months 
after the trial using the same questionnaire applied prior to the trial. A l l 14 smokers in 
the control group are reported to be smokers, therefore, the failing rate in the control 
group is 100%. However, amongst the 49 smokers in the treatment group, 2 smokers 
who had managed to reduce smoking consumption at the end of the 9-day trial 
smoked daily cigarettes at the same level as before the trial began, therefore 18.4% 
(nii?9) o f smokers ,failed to quit smoking 3 months after the trial. 40 smokers have 
managed, either to give up their habit completely or reduce their daily smoking 
consumption. The overall effective rate is therefore 81.6% (n^40) a^ shSWfi in Figure 
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4.6. The overall effectiveness of Zhong Mai Yan Ke is shown to be statistical 
significant (Fisher's exact test, P- value<0.001). 
Figure 4.6 Treatment Effect at 3 months after the trial 
Two groups in the trial 
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80 
60-
^ 40 
(U 
P 
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Effect of method 
• treatment group 
• control group 
In the light o f the results 3 months afl:er the trial, it can be said Zhong Mai Yan ke is 
an effective agent for smoking cessation as 42.9% (n=21) o f those who initially quit 
managed to refrain f rom smoking, 19 smokers (38.8%)) managed to reduce the 
smoking consumption and 9 smokers (18.4%)) had not changed in smoking habit 3 
months after the trial (table 4.6 and figure 4.7). Compared with the results at the end 
o f the 9-day trial, it is shown that the effectiveness o f Zhong Mai Yan Ke 3 months 
after the trial is not as good as that at the end o f the 9-day trial (table 4.6 and figure 
4.8) but is still considered highly effective. It would be useful to fol low up the 
smokers for another 12 months in order to ascertain the permanent effect o f Zhong 
Mai Yan Ke. 
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Table 4.6 Percentage of success at the end of the 9-day trial and 3 months after the trial 
smoking status at the end of 
the 9-day trial 
3 months 
after the trial 
treatment 
group 
complete success (quit 
smoking) 
25 
(51.0%) 
21 
(42.9%) 
partial success (manage to 
reduce smoking consumption) 
17 
34.7% 
19 
(38.8%) 
Failure (no change in smoking 
habit) 
7 
(14.3%) 
9 
(18,4%) 
total 49 
(100%) 
49 
(100%) 
control 
group 
complete success(quit 
smoking) 
0 
(0%) 
0 
(0%) 
partial success (manage to 
reduce smoking consumption) 
0 
(0%) 
0 
(0%) 
Failure (no change in smoking 
habit) 
14 
(100%) 
14 
(100%) 
total 14 
(100%) 
14 
(100%) 
Figure 4.7 Percentage of quitting smoking, partial smoking and having no change in 
smoking habit (no effect) 3 months after the trial 
no effect partial reduction quit smoking 
Effect 
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Figure 4.8 Smoking status in the treatment group at the end of the 9-day trial and 3 
months after the trial 
60 
no effect partial reduction quit smoking 
at the end of the 
9-day trial 
3 months after 
the trial 
Effect 
The results also showed that a small proportion o f those treated, who were initially 
able to quit completely, 4 had relapsed and had taken up smoking again to quit 
smoking completely at the end o f the 9 day trial. So the sustained quitting rate was 
81.4% (21/25). The relapse rate was 16% (4/25) f rom the initial quitters; however, it 
was reported they smoked fewer than before the trial. In the partially successful group, 
it was reported that 10 out o f the 17 had increased their smoking consumption 
including 8 (47.1%) who were smoking more cigarettes per day than at the end o f the 
9-day trial but less than that before the trial began and 2(11.8%)) who were smoking 
the same amount o f cigarettes as before the trial began. So the sustained reducing 
smoking consumption was 41.2%o (7/17) (table 4.7 and figure 4.9). 
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Table 4.7 Smoking status at the end of the 9-day trial and 3 months after the trial 
at the end of the 9-day trial 3 months after the trial 
smoking status N smoking status N 
treatment 
group 
quit smoking 25 quit smoking 21 
relapse but smoking less than 
before the trial began 
4 
manage to reduce 
smoking 
consumption 
17 smoke the consumption as same 
as that at the end of the 9-day 
trial 
7 
smoke consumption more than 
that at the end of the 9-day trial 
8 
smoke consumption as same as 
that before the trial 
2 
no change in 
smoking habit 
7 no change in smoking habit 7 
total 49 49 
control 
group 
quit smoking 0 quit smoking 0 
manage to reduce 
smoking 
0 manage to reduce smoking 
consumption 
0 
no change in 
smoking habit 
14 no change in smoking habit 14 
total 14 14 
Figure 4.9 Smoking status of initially successfully treated smokers at 3 months 
90 
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Status at Day 9 
• F^rtlal reduction at 
Day 9 
• No smoking at Day 9 sustained effect but complete 
effect relapse relapse 
Smoking status of the subjects in the treatment group excluding failing to 
quit at the end of the 9-day trial 
At the end of 3 months, of those'who were treated with Z M Y K , 2 r cases (42.9%)) 
qiiitted smokinYsuccessful fy, S cases (10t2%)) smoked less than 1/3 of the niimber at 
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Day 9, 7 cases (14.3%i) smoked between 1/3 and 1/2 o f the number at Day 9, 7 cases 
(14.3%) smoked more than V2 o f the number at Day 9 and 9 cases (18.4%)) smoked the 
same number 3 months after the trial. In the control group, all the subjects who 
applied placebo patches, no effect on smoking cessation was seen at the end of 3 
months (table 4.8). 
Table 4.8 effect groups * treatment group degree of addiction obtained 3 months after 
the trial 
group 
total treatment 
group 
control 
group 
no change in smoking habit 9 (18.4%) 
14 
(100.0%) 
23 
(36.5%) 
smokes more than 1/2 of the 
number at Day 9 
7 
(14.3%) 
0 
(0%) 
7 
(11.1%) 
effect 
smokes between 1/3 and 1/2 of 
the number at Day 9 
7 
(14.3%) 
0 
(0%) 
7 
(11.1%) 
groups smokes but less than 1/3 of the 
number at Day 9 
5 
(10.2%) 
0 
(0%) 
5 
(7.9%) 
quit smoking 21 (42.9%) 
0 
(0%) 
21 
(33.3%) 
total 49 
(100.0%) 
14 
(100.0%) 
63 
(100.0%) 
A t the end of 3 months, 2 people who smoked more than V^ o f their pretreatment level 
at Day 9, had increased their consumption o f cigarettes back to their baseline number. 
4 people who smoked between 1/3 and 14 o f the number at the end o f 9-day trial had 
increased their consumption o f cigarettes to more than V-i o f the number at Day 9 
dependence level after three months. 4 people who smoked less than 1/3 o f the 
number at Day 9 had increased their consumption o f cigarettes to between 1/3 and Vi 
o f the number at Day 9 after three months. 4 people who quitted smoking at the end of 
9-day trial had taken up smoking again and their consumption o f cigarettes had less 
than 1/3 o f the the number at Day 9 after three months (table 4.9). 
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Table 4.9 treatment groups three months after the trial * treatment group at the 
end of the 9-day trial degree of addiction 
treatment group 
at the end of the Q-day trial 
Total 
no 
change 
in 
smoking 
habit 
smokes 
more 
than 1/2 
of the 
number 
at Day 
9 
smokes 
between 
1/3 and 
1/2 of 
the 
number 
at Day 9 
smokes 
less than 
1/3 of 
the 
number 
at Day 9 
quit 
smoking 
3 
months 
after the 
trial 
no change in 
smoking habit 
Count 
% within 
effect 
groups 
after 9 
days 
7 
100,0% 
2 
40.0% 
9 
18.4% 
smokes more 
than 1/2 of 
the number 
at Day 9 
3 
60.0% 
4 
57.1% 
7 
14.3% 
smokes 
between 1/3 
and 1/2 of the 
number at 
Day 9 
3 
42.9% 
4 
80.0% 
7 
14,3% 
smokes less 
than 1/3 of 
the number 
at Day 9 
1 
20.0% 
4 
16.0% 
5 
10.2% 
quit smoking 21 
84.0% 
21 
42.9% 
total 7 
100.0% 
5 
100.0% 
7 
100.0% 
5 
100.0% 
25 
100.0% 
49 
100,0% 
Further analysis of the successful quitters at the end of the 9-day treatment and at 3 
months after the trials reveals that 3 of the 21 were heavy smokers, e.g. smoking over 
21 cigarettes per day, and have smoked for more than 10 years. The remaining 4 
smokers who have successfully given up smoking were moderate smokers, e.g. 
smoking 11-20 cigarettes per day, and have smoked for less than 10 years. However, 
there is no strong relationship between age, length of smoking experience and degree 
of addiction amongst those 4 smokers who took up smoking again 3 months after the 
trial. Amongst those 17 smokers who managed to reduce their daily consumption, 10 
of them had increased their daily intake 3 months after the trial. Taking all these 
factors into consideration it can be said Zhong Mai Yan Ke is equally effective for a 
range of smokers. 
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3. Currently treatment effects on different age groups, years of smoking groups and 
degree of addiction groups 
a) Relationship between effectiveness of Zhong Mai Yan Ke and Age 
It is found that the rate of quitting smoking is highest (90.9% at the end of 9-day trial 
and 77.3% obtained 3 months after the trial) in the age group between 21 and 30 years 
old. Those who were aged over 60 were not at all responsive to Zhong Mai Yan Ke. 
Although the sample is too small to be conclusive, in general it appears that the 
success rate is higher among younger people than it is among the older people (table 
4.10). 
Table 4.10 Relationship between effectiveness of Zhong Mai Yan Ke and age 
effect group 
age groups 
Total 20 to 30 
years old 
11 to 40 
ears old 
41 to 50 
years old 
51 to 60 
years old 
over 60 
years old 
at the end of 
the 9-day trial 
(underlined) 
3 months after 
the trial (bold) 
no change in 
smoking 
habit 
0 
(0%) 
1 
(9.1%) 
0 
(0%) 
3 
(50.0%) 
3 
(100.0%) 
7 
(14,3%) 
0 
(0%) 
2 
(18.2%) 
0 
(0%) 
4 
(66.7%) 
3 
(100.0%) 
9 
(18.7%) 
smokes more 
than 1/2 of 
the number 
at Day 9 
0 
(0%) 
0 
(0%) 
1 
(9.1%) 
2 
(18.2%) 
1 
(14.3%) 
3 
(42.9%) 
3 
(50%) 
2 
(33.3%) 
0 
(0%) 
0 
(0%) 
5 
(10,2%) 
7 
(14.3%) 
smokes 
between 1/3 
and 1/2 of 
the number 
at Day 9 
1 
(4.5%) 
3 
(13.6%) 
3 
(27.3%) 
2 
(18.2%) 
3 
(42.9%) 
2 
(28.6%) 
0 
(0%) 
0 
(0%) 
0 
(0%) 
0 
(0%) 
7 
(14.3%) 
7 
(14.3%) 
smokes less 
than 1/3 of 
the number 
at Day 9 
1 
(4.5%) 
2 
(9.0%) 
2 
(18.2%) 
2 
(18.2%) 
2 
(28.6%) 
1 
(14.3%) 
0 
(0%) 
0 
(0%) 
0 
(0%) 
0 
(0%) 
5 
(10.2%) 
5 
(10.2%) 
quit smoking 
20 
(90.9%) 
17 
(77.3%) 
4 
(36.4%) 
3 
(27.3%) 
1 
(14.3%) 
1 
(14.3%) 
0 
(0%) 
0 
(0%) 
0 
(0%) 
0 
(0%) 
25 
(51.0%) 
21 
(42.9%) 
total 
22 
(100.0%) 
22 
(100.0%) 
11 
(100.0%) 
11 
(100.0%) 
7 
(100.0%) 
7 
(100.0%) 
6 
(100.0%) 
6 
(100.0%) 
3 
(100.0%) 
3 
(100.0%) 
49 
(100.0%) 
49 
(100.0%) 
61 
b) Relationship between effectiveness of Zhong Mai Yan Ke and duration of smoking 
in years 
It is found that the rate of quitting smoking is highest (88.0% at the end of 9-day trial 
and 76.0% obtained 3 months after the trial) in the group where the number of years 
smoked is 10 years or less. Those whose number of years smoked were over 30 had 
the highest rate (57.1 % at the end of 9-day trial and 71.4%o obtained 3 months after the 
trial) of no change in their smoking habit. Although the sample is too small to be 
conclusive, in general it appears that the success rate was higher among smokers who 
had smoked for fewer years (see table 4.11). 
Table 4.11 Relationship between effectiveness of Zhong Mai Yan Ke and duration of 
smoking in years 
effect group 
number of years smoked 
10 years 
or less 
1 to 20 
ars 
21 to 30 
/ears 
over 31 
/ears 
lotal 
at the end of 
the 9-day trial 
(underlined) 
no change in 
smoking habit 
0 
fO%) 
1 
(10.0%) 
2 
(28.6%) 
4 
(57.1%) 
7 
(14,3%) 
1 
f4.0%) 
1 
f11.1%) 
2 
(25.0%) 
5 
(71.4%) 
9 
(18.7%) 
smokes more 
than 1/2 of 
the number 
at Day 9 
1 
(4.0%) 
1 
(10.0%) 
0 
(0%) 
3 
(42.9%) 
5 
(10.2%) 
0 
(0%) 
2 
(22.2%) 
3 
(37.5%) 
2 
(28.6%) 
7 
(14.3%) 
smokes 
between 1/3 
and 1/2 of the 
number at 
Day 9 
1 
(4.0%) 
3 
(30.0%) 
3 
(42.9%) 
0 
(0%) 
7 
(14.3%) 
3 
(12.0%) 
2 
(22.2%) 
2 
(25.0%) 
0 
(0%) 
7 
(14.3%) 
3 months 
after the trial 
(bold) 
smokes less 
than 1/3 of 
the number 
at Day 9 
1 
(4.0%) 
2 
(20.0%) 
2 
(28.6%) 
0 
(0%) 
5 
(10.2%) 
2 
(8.0%) 
2 
(22.2%) 
1 
(12.5%) 
0 
(0%) 
5 
(10.2%) 
quit smoking 
22 
(88.0%) 
3 
(30.0%) 
0 
(0%) 
0 
(0%) 
25 
(51.0%) 
19 
(76.0%) 
2 
(22.2%) 
0 
(0%) 
0 
(0%) 
21 
(42.9%) 
total 
25 
(100.0%) 
10 
(100.0%) 
7 
(100.0%) 
7 
(100.0%) 
49 
(100.0%) 
25 
(100.0%) 
9 
(100.0%) 
B 
(100.0%) 
7 
(100.0%) 
49 
(100.0%) 
c) Relationship between effectiveness of Zhong Mai Yan Ke and the degree of 
-smoking addiction 
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It is shown in table 4.12, that those smokers in the treatment group who smoked 
between 10 to 20 cigarettes per day achieved the highest rate (91.7% at the end of 9-
day trial and 79.2% obtained 3 months after the trial) of quitting smoking. Those 
smokers who smoked over 31 cigarettes per day achieved the highest rate (54.5% at 
the end of 9-day trial and 3 months after the trial) of no change in their smoking habit. 
It is found the percentage of smokers that stopped completely differs significantly for 
the different groups of degree of smoking addiction (X^-test, P value<0.001); the 
percentage of smokers that managed to reduce their smoking differs significantly for 
different groups of degree of smoking addiction (X^-test, P value<0.05). 
Table 4.12 Relationship between effectiveness of Zhong Mai Yan Ke and degree of 
smoking addiction 
effect group 
number of cigarettes smoked 
Total 10 to 20 
cigarettes 
21 to 30 
cigarettes 
over 31 
cigarettes 
at the end of 
the 9-day tria 
(underlined) 
no change in 
smol<ing habit 
0 
fO%) 
1 
(7.1%) 
5 
(54.5%) 
7 
(14.3%) 
0 
fO%) 
3 
(21.4%) 
6 
(54.5%) 
9 
(18.7%) 
smol<es more 
than 1/2 of the 
number at 
Day 9 
0 
fO%) 
3 
(21.4%) 
2 
(18.2%) 
5 
(10.2%) 
0 
(0%) 
4 
(28.6%) 
3 
(27.3%) 
7 
(14.3%) 
smoi<es 
between 1/3 
and 1/2 of the 
number at 
Day 9 
1 
f4.2%) 
5 
(35.7%) 
1 
(9.1%) 
7 
(14.3%) 
3 
(12.5%) 
3 
(21.4%) 
1 
(9.1%) 
7 
(14.3%) 
3 months 
after the 
trial (bold) 
smol<es less 
than 1/3 of the 
number at 
Day 9 
1 
(4.2%) 
2 
(14.3%) 
2 
(18.2%) 
5 
(10.2%) 
2 
(8.3%) 
2 
(14.3%) 
1 
(9.1%) 
5 
(10.2%) 
quit smoking 
22 
(91.7%) 
3 
(21.4%) 
0 
(0%) 
25 
(51.0%) 
19 
179.2%) 
2 
(14.3%) 
0 
0^%) 
21 
f42.9%) 
total 
24 
hoo.0%) 
14 
(100.0%) 
11 
(100.0%) 
49 
(100.0%) 
24 
(100.0%) 
14 
(100.0%) 
11 
(100.0%) 
49 
flOO.0%) 
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It was found that 51.0% (n=25) of smokers in the treatment group achieved complete 
success, i.e. gave up smoking completely, and 85.7% (n=42) managed to reduce their 
smoking at the end of the 9-day treatment period; the sustained quitting rate in the 
treatment group, i.e. 3 months after the trial, was 42.9% (n=21) and the rate of 
managing to reduce the smoking was 81.6% (n=40). In the light of the findings, a 
conclusion may therefore be drawn that Zhong Mai Yan Ke is an effective agent for 
smoking cessation and has achieved more than the predicted level of success specified 
in the hypothesis, i.e. at least 30% of the smokers in the treatment group wil l be able 
to reduce the number of cigarettes smoked per day and at least 20% will be able to 
give up the habit completely at the end of the 9-day trial; at least 20% of the smokers 
in the treatment group will be able to reduce the number of cigarettes smoked per day 
and at least 10% wil l be able to give up the habit completely 3 months after the trial. 
Whilst 51% of treated subjects managed to quit smoking completely at day 9, many 
(42.9%) still managed to maintain their success at the end of 3months. Even more 
encouraging, those who were smoking for less than 10 years, 22 (88%)) of them 
successfully stop smoking at day 9 and 19 (76%) managed sustain that at 3 months. 
Within the treatment group, there were 7 smokers at the end of the 9-day trial and 9 
smokers obtained 3 months after the trial had no change in smoking habit. 7 smokers 
at the end of the 9-day trial and 8 of 9 smokers obtained 3 months after the trial 
smoked 30 cigarettes or more per day; 6 of these 7 smokers at the end of the 9-day 
trial and 7 of these 9 smokers obtained 3 months after the trial had smoked for 20 
years or more. One can argue therefore, Zhong Mai Yan Ke is not effective for heavy 
smokers and those who have been addicted for a long period of time (table 4.7 and 
4.8) 
4.2.3 Side effects 
Some systemic side effects occurred at the end of the 9-day trial, such as nausea and 
dizziness when applying Zhong Mai Yan Ke. 41 smokers (83.7%) experienced no side 
effects; 3 smokers (6.1%) felt nausea, 2 smokers (4.1%) felt dizziness and 3 smokers 
(6.1%) felt dizziness and nausea (table 4.13). 
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Table 4.13 side effects when applying Zhong Mai Yan Ke, i.e. during the course of the 9-
day trial 
Frequency Valid 
Percent 
Valid no side effects 41 83.7 
nausea 3 6.1 
dizziness 2 4.1 
dizziness and nausea 3 6.1 
Total 49 100.0 
We asked the smokers who had suffered from side effects to explain the 
uncomfortable feelings in detail by telephone. 
Smoker 1 
" I feel a little nausea and suffer from poor appetite during the treatment course of 9 
days. I feel better when I withdraw the patches." 
Smoker 2 
"Nausea, mainly nausea, is not only for cigarettes, but also for other foods." 
Smoker 3 
" I do not feel good, dizziness bothers me and I do not want to eat food and I feel 
nausea when I try to smoke." 
Smoker 4 
" I feel dizziness and this feeling disappears when I withdraw the patches." 
Only one smoker who applied ZMYK and another one who applied placebo plaster 
suffered from slight red rashes on the skin during the 9-day trial. People who have 
sensitive skin can suffer form an allergic reaction when he applies the patches. So this 
event could be a barrier against use of these patches just as with nicotine patch. Also 
this side effects form placebo plaster as future studies may be limited by this event. 
No one suffered from any side effects at three months after the trial. That means some 
side effects such as nausea and dizziness will disappear when people stop applying 
Zhong Mai Yan Ke. In the light of the findings, it can be said Zhong Mai Yan Ke is an 
effective agent for smoking cessation and that the hypothesis is proven, i.e. smokers in 
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the treatment group experience minor side effects as indicated by the manufacturer of 
Zhong Mai Yan Ke. 
4.3 Summary 
64 smokers were recruited in the clinical trial, 50 in treatment group and 14 in control 
group. The initial results and the 3 months follow-up data suggest that Zhong Mai Yan 
Ke is an effective smoking cessation agent for young people and those who have 
smoked for less than 10 years. It is not effective for those who are older than 50 years 
of age and have smoked for more than 30 years or more. 
The rates of quitting smoking completely in the active treatment group were 51.0% at 
the Day 9 and 42.9% at 3 months after the trial. 85.7% of the subjects at Day 9 and 
81.6% at 3 months of the study, managed to reduce their smoking (i.e either stopping 
completely or reducing the number of cigarettes smoked per day. At 3 months of the 
study 2 smokers smoked the same number of cigarettes as before. 12 smokers smoked 
more cigarettes per day at 3 months after the trial than that at the end of the 9-day 
trial, ranging from 3 to 9. 14 smokers in the control group who applied the placebo 
bandages were unsuccessful in smoking cessation. 100% of them did not quit smoking 
at all nor managed to reduce the number of cigarettes smoked per day. 
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Chapter 5 
Integrating Allopathic Medicine and 
Traditional Chinese Medicine (TCM) 
5.1 The present situation of smoking and smoking cessation in the 
world 
It is well known that smoking is harmful to people's health. It has a bad effect on 
families and on national economies. During the past decade, people and governments 
have campaigned against smoking. Most smokers want to quit, but they find it 
difficult to do successfully because they experience the well-characterised barriers, 
and withdrawal symptoms during their attempts to quit. In Western countries, many 
kinds of methods to stop smoking have been carried out, such as social movements, 
health education, advice and encouragement. 
The basic premise of Western medicine or allopathic medicine is founded on the 
principle of diagnosis and intervention. The study of anatomy, physiology, 
biochemistry and other related subjects provides the basic understanding of how the 
human body ftinctions and how to deal with disease processes. The management of 
diseases in this branch of medicine relies by-and-large on the use of pharmaceutical 
products to control or minimise symptoms. Surgery is one example of an intervention 
where doing therapies cannot succeed. In recent years, many kinds of medicines. 
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health products and therapies for quitting smoking, such as Nicotine Replacement 
Therapy (NRT), and non-nicotine drugs have been tried to help smokers to quit in 
both Western and Eastern countries. However, the effectiveness of these products is 
not high and they can not help all smokers to cease successfully. At the same time 
practitioners of Traditional Chinese Medicine (TCM) have been seeking effective 
treatment method for smoking cessation, such as acupuncture. 
TCM has a long history and dates back to the ancient times. As early as the late 
period of the New Stone Age, around 2700 B.C., Chinese Ancestors in the Yellow 
River valley primarily summed up their primitive experiences in herbs, acupuncture, 
massage etc. which had gradually been accumulated by their forefathers in their 
struggle for life and fight against nature. This turned spontaneous reactive medical 
behaviour that originated from a self-defence instinct, into a medical mode for the 
early human race. In the past 5000 years, social changes promoted the development of 
such ancient medicines. Sui and Tang Dynasties were a flourishing age for TCM. 
Thanks to the rapid development of China's politics, economy, culture, transportation 
and the excellent situation of cultural exchange with foreign countries during that 
period, TCM was also introduced into Korea, Japan, Arabian countries, etc. and it 
promoted the development of this branch of medical science in those countries. For 
example, "Law and Decrees of Tai Bao" issued during the Tai Bao years (701-703) of 
Japan's Civil and Military Dynasty, stipulated massage as one of the compulsory 
courses for medical students. This laid a solid foundation for "the three manipulating 
skills" that remain current now in Japan. 
Over the last century, TCM has co-existed with allopathic medicine in China. There 
are 350,000 staff working in more than 2,500 hospitals of traditional medicine in 
China. In addition, 95% of general hospitals have units for TCM and 50% of rural 
doctors are able to provide both traditional and allopathic medicine. 
In China, there are 800 manufacturers of herbal products. There are 170 research 
institutions across the country with perhaps the most prestigious being the Academy 
of TCM in Beijing. Chinese people believe the effectiveness of TCM and would like 
to be treated by using TCM. So TCM might be more appropriate and useful in China. 
Unfortunately, the channels for communication in this field between the West and 
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East are poor. Consequently, some good examples of practice and research evidence 
have not been disseminated. One of the reasons may also be that since TCM, 
particularly herbal medicines have been used for many centuries - providing evidence 
is not seen to be important. 
Nonetheless, TCM, including acupuncture, herbs and massage, etc. is gradually 
introduced to the outside world because it can produce unexpectedly positive effects 
with fewer side effects for many diseases. Acupuncture especially is accepted in 
Western countries, partly due to its fast therapeutic effect. For example, there are 
more than 3,000 TCM clinics registered in England now, according to yellow pages. 
The main TCM approach for smoking cessation is the acupuncture-needling Tim Mee 
acupoint. Practitioners of Traditional Chinese Medicine seek to regulate the balance 
of two different types of energy - ying and yang with acupuncture therapy through the 
meridians and collaterals, which are the roads that serve as transporting energy within 
the human body. Acupuncture therapy is to treat diseases through stimulating certain 
acupoints on the body surface. Acupoints are the specific sites where the energy 
within the human body through the meridians and collaterals is transported to the skin 
and are located on the meridians and collaterals. In recent years, acupuncturists 
attempted to promote smoking cessation by stimulating Tim Mee acupoints on both 
hands. However, the effectiveness is different depending on various acupuncture 
techniques. In recent years, a new herbal patch for smoking cessation, Zhong Mai Yan 
Ke, which conquers these disadvantages, has been used to substitute acupuncture 
treatment completely. It contains Cloves, Cassia, Areca and biological magneto-
therapy, acts on Tim Mee acupoint on the wrists of both hands, stimulates taste, sense 
and nerve system of the human body and changes the smell of cigarette smoking to 
stop smoking. It is claimed that the rate of effectiveness (quitting completely and 
reducing cigarettes per day) of Zhong Mai Yan Ke for smoking cessation is 85% and 
has no serious side effects. 
5.2 Some comparisons between allopathic interventions and 
traditional Chinese Medicine (TGM) 
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The effectiveness and side effects of allopathic interventions and Traditional Chinese 
medicine (TCM) can be compared (See table 5.1). 
Table 5.1 Compare among different smoking cessation products 
Product 
Form of 
prepared 
drugs 
Brand 
Function Therapeutic Regimen Advantages 
Side 
effects Efficacy 
Habitrol 
21mg/day 
(4 wks), 
14mg/day 
about 
20-30% 
at 6 
months 
Nicotine 
Patches 
Nicotine 
Transderma 
(2 wks), 
7mg/day (2 
wks) 
easy to use 
itching or 
redness of 
the skin 
Nicoderm 
CQ 
absorption 
through 
skin 
14mg/day 
(6 wks), 
7mg/day (2 
wks) 
Nicotrol 15 mg/day for 6 wks 
Nicotine 
Gum 
Nicorette 
(2mg/piece) 
absorption 
through 
the lining 
of the 
mouth 
9 pcs/day 
(6 wks), 6 
pcs/day (3 
wks), 3 
pcs/day (3 
wks) 
far safer than 
cigarette 
smoking 
jaw 
fatigue 
and 
soreness, 
gaseous 
distension, 
hiccups 
and 
nausea 
27% at 6 
months 
and 23% 
at 12 
months 
Nicotine 
Nasal 
Sprays 
Nicotrol 
absorption 
through 
the lining 
of the 
nose 
64 
squirts/day 
for 12 wks 
rapid delivery 
and relatively 
high plasma 
concentrations 
irritation 
of nose 
and throat 
32% at 6 
months 
and 26% 
at one 
year 
Nicotine 
Inhaler 
Nicotrol 
Inhaler 
absorption 
through 
the mouth 
24mg/day 
for 12 wks 
reduce fears 
associated 
with abrupt 
cessation of 
the hand-to-
mouth ritual 
irritation 
of throat 
and mouth 
29% at 6 
wks and 
24% at 3 
months 
Non-
nicotine 
products 
Zyban 
absorption 
through 
the 
stomach 
and 
intestines 
300mg/day 
for 7-12 
wks 
(150mg/day 
for first 
3 days) 
be suitable for 
the smokers 
who either 
cannot 
tolerate NRT 
or prefer non-
nicotine 
treatment 
dry mouth 
and 
insomnia 
27% at 6 
months 
after the 
treatment 
Traditional 
Chinese 
Medicine 
(TCM) 
Zhong Mai 
YanKe 
(ZMYK) 
absorption 
through -
skin 
2 pics/day 
~ for 18^ays" - natural herbs 
nausea 
and 
dizziness 
when 
applying 
42.9% at 
3 months 
-after the 
treatment 
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It shows that Traditional Chinese Medicine is more effective for stopping smoking 
and lack of side effects. The cost of ZM YK is cheaper than that of allopathic 
interventions which are used in England because ZM YK is made of herbs and made 
in China where there are plenty of herbs and ZMYK is purchased according to the 
expense level of Chinese people. So it must be cheaper for English people i f it is 
allowed to be sold in England. 
In China, people believe the effectiveness of Traditional Chinese Medicine because it 
has been developed for about 5000 years. And herbs are planted everywhere. So 
Traditional Chinese Medicine might be more appropriate in China now. 
5.3 A critical analysis of the study 
In order to test the claim, this therapeutic trial to ascertain the extent of the effect of 
Zhong Mai Yan Ke was designed. Blind controlled studies are able to measure 
"genuine" quantitative differences between placebo and the active ingredient. 
However, only an open randomised controlled trial was possible for this project, here 
in this commercial and culture setting in China as discussed in chapter 3. It was 
inevitable the study was carried out as an open randomised trial. 
The trial was only completed in China because Zhong Mai Yan Ke and the placebo 
Band-aid super-elastic adhesive are legally licensed medicines and commonly known 
in China. It was impossible to alter the packaging or their presentation to make them 
appear completely similar. Moreover, many people, including smokers, knew there 
was a magnetic disc in the patch of ZMYK whilst the Band-aid adhesive bandage did 
not include any magnetic discs. That meant that the volunteers always knew i f the 
product they used was ZMYK by checking i f a disc was in it. This was then an open 
trial. 
In^the trial 64 volunteers were recruited, based on the inclusion and exclusion criteria. 
50 in the treatment group applied Zhong Mai Yan Ke for 9 days and 14 in the control 
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group used placebo for 9 days. In the treatment group, the rates of quitting smoking 
completely in the treatment group were 51.0% at the end of the 9 day trial and 42.9% 
at three months after the trial. Results in those managing to reduce smoking (quitting 
smoking completely and reducing cigarettes smoked per day) were 85.7% at the end 
of the 9 day trial and 81.6% three months after the trial. Smokers in the control group 
who applied the placebo bandages were unsuccessftil in smoking cessation or 
reduction. 
Zhong Mai Yan Ke was more effective for younger people and those who had smoked 
for less than 10 years. It was not effective for those who were older than 50 years and 
had smoked for 30 years or more. 
Overall the results showed that ZMYK was effective in helping smokers to quit and to 
reduce their rate of smoking. No one reported side effects at three months. The initial 
side effects such as nausea and dizziness disappeared when people stopped applying 
Zhong Mai Yan Ke. 
5.4 The future research directions 
In this study, the application of herbal medicine in the treatment of nicotine addiction 
was shown to be of benefit to a small sample of smokers. A blinded randomised 
controlled trial would need to be carried out in the West to confirm that these results 
are reproducible. 
This acupuncture based herbal patch might have a role in the UK i f it were marketed 
because it contains natural herbs and not nicotine and because it can conquer the 
disadvantages of traditional acupuncture. For example, some people are afraid that 
needles would cause pain. It takes 20 to 30 minutes to complete one session of 
acupuncture treatment. The greatest advantage of patches is that they are convenient 
to apply and saving time. People can apply the patch themselves. I f truly successful in 
the Western setting such patches would be welcomed. 
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5.5 Summary 
This therapeutic trial ascertained the extent of the effect of Zhong Mai Yan Ke using 
an open randomised controlled trial. The results showed that ZMYK was effective in 
stopping smoking and that there are no lasting side effects. More research using a 
double blind trial, in a Western setting is needed before the resufts can be generalised. 
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Appendix Bi 
Poster 
Dear. 
We are carrying out research into helping smokers to give up smoking 
using Zhong Mai Yan Ke and placebo patches. Volunteers will be 
randomly allocated to Zhong Mai Yan Ke and placebo. 
Zhong Mai Yan Ke which is composed of various kinds of Chinese herbs 
and a biological magnet flake needs to be applied on the acupoint of 
Timmei on the wrist. The patches are not very noticeable. Only a few 
users may have experienced any unpleasant effects, which will 
disappeared upon removal of the patches. 
Band-aid super-elastic adhesive bandage are used as placebo patches. 
There is no any medication in it. So there is no any side effect when 
applying them. 
The trial lasts for 9 days. You will be requested to complete some 
questionnaires at the outset of the trial and at the end of the 9-day trial. 
The follow-up data 3 months after the trial need to be collected using a 
telephone interview technique. 
I f you are interested in taking part please contact: 
Shujuan Yao on 2466496 (help line) 
Northeast Centre for selling Zhong Mai Yan Ke 
188 Taiyuan Street 
Northeast Road 
Xigang District 
116012 
You can discontinue with the treatment at any time i f you wish and it 
does not affect the treatment or service you will be provided in the 
further. 
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Appendix B: 
H E A L T H SCREENING QUESTIONNAIRE 
Name Date of birth. 
Please answer all of the following questions. If you answer yes, please give further details, 
continuing on a separate piece of paper if necessary. 
Yes No Details 
Have you ever been treated in hospital? If yes, 
please give reason(s) and dates. 
Have you seen a doctor in the last year for any 
kind of health problem? If so please give 
reason(s). 
Are you having any treatment or investigations of 
any kind at the moment? 
Are you waiting for any treatment, operation or 
investigation? 
Have you ever had any illness or health related 
problem that may have been caused or made 
worse by your work? 
Have you ever been medically retired from any job, 
or left any job because of ill health? 
Have you had any days off sick in the last 3 years? 
If yes, please give number of days and reasons to 
the best of your recollection. 
Do you have any eyesight problems not corrected 
with glasses? 
Do you have any hearing problems? 
Do you have any difficulties standing, bending, 
lifting or with any other movements? 
Have you ever had any back problem? 
Have you ever had any problem with your joints 
including pain, swelling or stiffness? 
Have you ever suffered from any mental illness, 
psychological or psychiatric problem, including 
depression, anxiety, nervous debility, nervous 
breakdown7s~chiz6ph7enia 6r~ealing~aisorder 
(anorexia or buNmia)? 
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Have you ever had a drug or alcohol problem? 
Have you ever had fits, blackouts or epilepsy? 
Have you ever had any skin problems? 
Have you ever had any heart or blood pressure 
problems? 
Have you ever suffered from asthma, bronchitis or 
chest problems? 
Have you ever had treatment for tuberculosis 
(TB)? 
Have you ever had hepatitis or jaundice? 
Do you have any other medical conditions? 
At present, are you on any medication or 
Traditional Chinese Medicine (TOM), such as 
acupuncture and herbal treatment? 
Do you feel well at present? 
If applicable, please state w/hether you are 
pregnant or not. 
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Appendix B3 
SURVEY OF SMOKING STATUS 
Please enter the following information: 
Name Age Sex: M 
1. How old were you when you started smoking? 
2. How many cigarettes do you smoke a day now? 
3. Have you tried giving up smoking? 
4. I f the answer to Question 3 is yes, how many times have you tried? 
5. I f the answer to Question 3 is yes, which method did you use? 
6. Do you want to quit smoking very much now? 
Consent for smoking cessation trial 
I , (Full name) , having been fully informed of the 
trial and any associated complications with the application of the patches, agree to 
undertake the trial. I will also consent to give personal information about my smoking 
habits and a contact telephone number and address for progress monitoring. 
I understand I can withdraw from the trial at any time. 
I have been assured any information given will be kept in the strictest confidence and 
will only be used for anti-smoking research purposes solely by Dr. Cheung's team. 
Signed 
Date 
Tel 
Address 
Thank you for completing this questionnaire. Please return the questionnaire 
immediately to Shujuan Yao. 
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Appendix C 
Volunteer instruction leaflet 
Dear. 
You wil l be given a supply of one box of Zhong Mai Yan Ke or 18 pieces placebo 
patches for 9 days. The application of these patches is very simple. Just remove the 
wrapper, and then apply the patches on both wrists at the acupoint of Tim Mee shown 
in the diagram. 
Firstly, massage the acupoint of Tim Mee shown in the diagram 10 minutes before 
application. Secondly, apply a patch once a day to each wrist at the acupoint and left 
in place for 22 hours and then remove the patch. A new patch should be applied to 
each wrist after 2 hours. 
Time for application: any time during the day 
Precaution: 
• Not edible 
• KEEP AWAY FROM CHILDREN 
• After each application, wash wrists with soap and water, and leave to air for 2 
hours, then apply new patches. 
• The effect of patches may make cigarettes taste insipid or bitter i f you apply 
Zhong Mai Yan Ke. It is a normal reaction. 
• Those who are extremely sensitive to Zhong Mai Yan Ke may occasionally 
feel slight dizzy, nauseated. 
• I f you want to discontinue the trial, please contact the "help line - 2466496 
(China)" immediately. 
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Appendix E 
The letter from dalian university in china 
iDslitute of Pharmacology 
School of Medicine 
Dalian University 
DaJian, Liaoning, 116622 
CHINA 
10 Januaiy 2004 
Professor Pali Hiingin. 
Wolfson Research Institute 
University of DuAara, Queen's Campus 
Thoniaby 
Stockton on Tees, TS17 6BH 
U.K.. 
Dear Professor Pali Hungin, 
In regard to^  Zhong Mai Yan Ke (ZMYK) trial conducted by Ms. Yuzhuo Wang in China, 
the trial is considered as an appropriate trial without ethical coTicems in China. 2MYK is 
a licensed and non-prescription product in China. It has been on the Chinese maikef for 
many years and is considered as a safe product by Chinese authority. 
I.wish you find tliati this infpnniiionis helpful. 
Yours sincerely, 
Professor Shirong Xie 
Director of Ibstitxite o f Pharmacology 
